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Arbete och Hälsa
Arbete och Hälsa (Work and Health) is a
scientific report series published by the
National Institute for Working Life. The
series presents research by the Institute’s
own researchers as well as by others, both
within and outside of Sweden.  The series
publishes scientific original works, disser-
tations, criteria documents and literature
surveys.
Arbete och Hälsa has a broad target-
group and welcomes articles in different
areas. The language is most often English,
but also Swedish manuscripts are
welcome.
Summaries in Swedish and English as well
as the complete original text are available
at www.arbetslivsinstitutet.se/ as from
1997.
Preface
The Criteria Group of the Swedish National Institute for Working Life (NIWL) has the
task of gathering and evaluating data which can be used as a scientific basis for the
proposal of occupational exposure limits given by the Swedish Work Environment
Authority (SWEA). In most cases a scientific basis is written on request from the SWEA.
The Criteria Group shall not propose a numerical occupational exposure limit value but,
as far as possible, give a dose-response/dose-effect relationship and the critical effect of
occupational exposure.
In searching of the literature several databases are used, such as RTECS, Toxline,
Medline, Cancerlit, Nioshtic and Riskline. Also information in existing criteria documents
is used, e.g. documents from WHO, EU, US NIOSH, the Dutch Expert Committee for
Occupational Standards (DECOS) and the Nordic Expert Group. In some cases criteria
documents are produced within the Criteria Group, often in collaboration with DECOS or
US NIOSH.
Evaluations are made of all relevant published original papers found in the searches. In
some cases information from handbooks and reports from e.g. US NIOSH and US EPA
is used. A draft consensus report is written by the secretariat or by a scientist appointed
by the secretariat. The author of the draft is indicated under Contents. A qualified
evaluation is made of the information in the references. In some cases the information can
be omitted if some criteria are not fulfilled. In some cases such information is included in
the report but with a comment why the data are not included in the evaluation. After
discussion in the Criteria Group the drafts are approved and accepted as a consensus
report from the group. They are sent to the SWEA.
This is the 24th volume that is published and it contains consensus reports approved by
the Criteria Group during the period July 2002 to June 2003. These and previously
published consensus reports are listed in the Appendix (p 67).
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1Consensus Report for Triethanolamine
October 23, 2002
This document is an update of the Consensus Report published in 1983 (46).
Chemical and physical data. Uses
CAS No.: 102-71-6
Synonyms: 2,2´,2´´-nitrilotriethanol
nitrilo-2,2´,2´´-(2-hydroxyethyl)amine
tris (2-hydroxyethyl) amine
2,2´,2´´-trihydroxytriethylamine
triethylolamine
TEA
Formula: C6H15NO3
Structure:
Molecular weight: 149.19
Boiling point: 335.4 °C
Melting point: 20.5 °C
Density: 1.12 g/cm3 (20 °C)
Vapor pressure: <0.001 kPa (20 °C)
Saturation concentration: <10 ppm
Conversion factors: 1 ppm = 6.19 mg/m3 (20 °C)
1 mg/m3 = 0.162 ppm (20 °C)
Triethanolamine (TEA) at room temperature occurs either as hygroscopic
crystals or as a viscous, clear to yellowish, hygroscopic liquid with a weak
odor of ammonia (19, 25, 28). It is a moderately strong base and mixes with
water, methanol and acetone (19, 21). TEA may contain diethanol amine and
monoethanol amine as impurities (6). In the presence of nitrite or nitrous oxides
TEA can form N-nitroso diethanolamine (19). Endogenous nitrosation of TEA
is presumed to be of negligible extent, however (25).
TEA is an ingredient in printing inks (product register, Swedish National
Chemicals Inspectorate). It is also used as a corrosion inhibitor in cutting fluids,
as a detergent, as an absorbent for acidic gases, as an additive in concrete/cement,
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2in the textile industry, and as an intermediate in the production of anionic
surfactants. TEA is also an ingredient in various cosmetics and medicines
(19, 27, 29).
Uptake, biotransformation, excretion
Absorption of TEA by the skin and digestive tract is both rapid and high. A
Japanese study (Kohri et al. 1982, cited in References 19 and 25) reports that
53 – 63% of an oral dose given to rats disappeared from the digestive tract within
about 30 to 60 minutes. In experiments in which 14C-labeled TEA, either undiluted
or blended in acetone or water, was applied to the skin of mice and rats (1000 -
2000 mg/kg b.w., 1.8 - 2 cm2) either with or without occlusion, uptake was over
70% within a period of 24 to 48 hours (most of it within 24 hours). Uptake was
calculated from excretion data and the amount of radioactivity remaining in
internal organs. The highest radioactivity level in blood was noted 2 to 3 hours
after the treatment (mice, 2000 mg/kg b.w., unoccluded). For undiluted TEA
(occlusion, 48 hours), the calculated absorption rates were 500 mg/cm2/hour for
mice and 2000 mg/cm2/hour for rats. Uptake was calculated by subtracting the
amount of radioactivity remaining at the site of application (44). It is clear that
skin absorption of TEA can result in significant systemic exposure.
Mice were given intravenous injections (1 mg/kg b.w.) or dermal applications
(2000 mg/kg b.w., unoccluded) of 14C-labeled TEA, and it could be shown that
TEA was eliminated from blood in two phases (i.v. 24 h: t1/2a = 0.3 h, t1/2b = 10 h;
dermal 48h: t1/2a = 1.9 h, t1/2b_ = 31 h) (44). In the same study it was found that
TEA is excreted primarily in urine in unmetabolized form (no metabolites were
found in analysis of mouse urine). Mice and rats given either intravenous injec-
tions (1 mg/kg b.w.) or dermal applications (1000-2000 mg/kg b.w.) of TEA
excreted 50 - 70% of the dose in urine (most of it during the first 24 hours) and
about 10 - 30% in feces (44). A Japanese study (Kohri et al. 1982, cited in
References 19 and 25) reports that rats given a single oral dose of TEA (2 - 3
mg/kg b.w.) excreted 53% unchanged in urine and 20% in feces within 24 hours.
Toxic effects
Human data
In an irritation test, pure TEA or a 1:1 solution of TEA in water was applied to
human skin under occlusion for 24 hours. The treatment resulted in little or no
erythema, and it was concluded that TEA was not irritating to skin (36). It should
be pointed out, however, that TEA tested with other vehicles or other exposure
times may cause skin irritation (see below).
Several cases of contact allergy to TEA have been reported in people exposed
to TEA in cutting fluids, cosmetics or medicines. In most of the earlier studies,
however, subjects were tested with concentration that are irritating to skin, and in
the light of present knowledge those test results are open to question. The test
3concentration now recommended is 2 to 2.5% in vaseline, although 2.5% in
vaseline is known to be slightly irritating (41). Evaluating the results of studies
(1, 3, 4, 5, 8, 10, 12, 13, 16, 18, 32, 34, 35, 38, 40, 45) in which higher test
concentrations and/or other vehicles were used is therefore difficult. Considering
the large number of people exposed to TEA in shampoos, cosmetics and other
skin preparations, contact allergy to TEA is fairly unusual (22).
There are some acceptably designed studies of contact allergy due to occupa-
tional exposure (Table 1). In a large German study of eczema patients who were
metalworkers, it is reported that of 295 subjects patch-tested with 2.5% TEA in
vaseline, one had a positive reaction (48). There are also a few case reports
describing cases of contact allergy to TEA among metalworkers, which were
diagnosed with acceptable tests (6, 37). There is also a study reporting that the
incidence of contact eczema on the hands and lower arms of workers increased
after a synthetic coolant containing TEA was introduced into the production
process. Patch tests with TEA (2.5% in vaseline) were given to 52 subjects with
contact eczema, and 3 had positive reactions (2).
Positive reactions to acceptable patch tests of TEA have also been reported in
contexts other than occupational exposure (Table 1). Data on 475 cases of contact
allergy to ingredients in cosmetics were reviewed in a large European retro-
spective study: 3 patients had a positive reaction to TEA (concentration and
vehicle not reported) (20). In a large German study, 14 of 2054 eczema patients
patch-tested with 2.5% TEA in vaseline had a positive reaction (41). The patients
were tested because of suspected allergy to various topical preparations. In
another study over 700 patients with suspected cosmetic or medicine-related
contact dermatitis (topical substances) were patch-tested with 2.5% TEA in
vaseline, and 20 had a positive reaction (47). There are also a few case reports
of contact allergy to TEA diagnosed by patch tests with acceptable concentrations
of TEA in vaseline (see Table 1).
In summary, it can be concluded from these studies that, considering its wide-
spread use, TEA rarely causes contact allergy.
There is a study (39) describing occupational asthma in two metalworkers
whose exposures included a cutting fluid containing TEA. One of them reported
coughing and shortness of breath during the workday, growing more severe
toward the end of the workweek. This patient was using a cutting fluid containing
85% TEA, and had been exposed to several substances including oil mist for over
10 years before the symptoms appeared. His spirometry values were normal, but
there was bronchial hyperreactivity. A provocation test with heated cutting fluid
containing TEA elicited a prompt reaction (within 1 hour), with a maximum drop
of 21% in PEF and a 13% reduction of FEV1. Tests with the same cutting fluid,
used cold, yielded an immediate drop of 18% in PEF. The other patient, whose
exposures included mists of turning and cooling fluids, reported coughing,
shortness of breath, chest tightness, rhinitis and eye irritation in connection with
work, and later on also coughing at night and noisy breathing. His spirometry
4Table 1. Reactions to TEA in patch tests given to eczema patients seen at dermatology
clinics.
Concentration Vehicle No. Positive/
No. Tested
Occupation/
Exposure
Ref.
2.5% Vaseline 3/52 Metalworkers 2
2% & 5% Vaseline 1/2, 2/2 Cosmetics 26
2.5% Vaseline 20/737 Cosmetics/medicine 47
2.5% Vaseline 1/295 Metalworkers 48
2.5% Vaseline 14/2054 Ointment base 41
0.5% & 5% Vaseline 1/1 Metalworker 37
2.5% Vaseline 1/1 Cosmetics/medicine 22
1.25% & 2.5% Vaseline 1/1 Grinder 6
Not given Not given 3/475 Cosmetics 20
1% & 5% Vaseline 1/1 Sunscreen 11
values were normal and he had no bronchial hyperreactivity. Provocation tests
with heated turning fluid containing 14% TEA caused an immediate drop of 17%
in PEF accompanied by wheezing, and provocation with cold “pure” TEA caused
an immediate drop of 21% in PEF. Two asthmatic control patients, one with mild
and one with moderate hyperreactivity, were exposed to heated TEA and to a
TEA aerosol without developing respiratory symptoms, and their PEF was
unaffected. According to the data in this study, there are two reported cases
of TEA-related asthma.
There is a report of an 8-year-old girl who sneezed uncontrollably upon
exposure to clothing and towels washed in a detergent containing 5% TEA. The
sneezing fits gradually disappeared after use of the detergent was stopped, but
resumed when the detergent was again used. Sneezing was also triggered by TEA
powder/solutions. A prick test was positive for TEA (10-7 – 10-4 M) but not for any
other ingredient in the detergent. A positive result was also obtained with the
Passive Cutaneous Anaphylaxis (PCA) test, and TEA-specific IgE was identified
in the serum of the patient. TEA induced dose-dependent histamine liberation
from the patient’s white blood cells. PCA tests given to controls were negative for
both specific IgE and histamine liberation (23).
Animal data
TEA given orally has low acute toxicity. The reported LD50 for experimental
animals is in the range 5.2 - 11.3 g/kg b.w. The reported LD50 for skin application
(rabbits, 24 hours, occlusion) is >20 g/kg b.w. (29).
Oral administration of 60 or 120 doses of 200, 400, 800 or 1600 mg TEA/kg
b.w. to guinea pigs (5 days/week by pipette) or rats (7 days/week in feed) resulted
in small, partially reversible histopathological changes in liver and kidneys (Table
2). The highest dose resulted in inflammation of renal tubuli but had no effect on
glomeruli. These changes were partially reversible. The animals given the lower
doses usually had smaller changes in their kidneys. Some fatty changes of the
5liver were observed in the guinea pigs at the two highest dose levels, but
histological examination 2 to 3 months after the final dose revealed no changes in
their livers. The lowest dose level had only slight effects on the kidneys (“slight
swelling with increased secretion”). According to the authors, in no case were the
observed kidney and liver changes severe enough to have any effect on function
(28). Dose-dependent growth inhibition and increased kidney weights were
reported in a cancer study (Table 2) in which rats were given 0, 1, or 2% TEA in
drinking water for 2 years (because of high mortality, the dose for females in both
dose groups was halved as of week 69). Histological examinations revealed
chronic nephropathy and other changes in kidneys, especially in the females.
There was no observed increase in the incidence of liver damage or pre-neoplastic
changes in the livers in any treated group, but there was a dose-dependent increase
in the occurrence of neoplastic nodules in the livers of the males (33). A sketchily
described study reports that deaths and histopathological changes in liver,
kidneys, spleen or testes were seen in rats given 730 mg TEA/kg b.w./day in
feed for 90 days (Table 2). Changes in liver or kidney weights were observed at
a dose level of 170 mg/kg b.w./day, but 80 mg/kg b.w./day was reported to have
no effect (42).
In a study in which 8 g TEA/kg b.w. was applied to the skin of guinea pigs
5 days/week (occlusion) the animals died after 2 to 17 applications. Changes in
liver, kidneys, lungs and adrenals were observed (28). When TEA was painted
onto the skin of mice (10, 33 or 100%, acetone vehicle; equivalent to about 150,
500 or 2150 mg/kg b.w.) 3 days/week for 13 weeks, males in the high-dose group
had lower lymphocyte counts and lower levels of alkaline phosphatases in serum
(p<0.05), but no other indications of systemic toxicity were noted in histopatho-
logical, hematological or clinical-chemical examination. The authors consider
these changes to be of uncertain biological relevance (14). In an unpublished
cancer study (NTP 1994, cited in Reference 29; NTP 1999, cited in Reference 25)
in which TEA in acetone was applied to the skin of rats 5 days/week for 2 years
(males: 32 – 125 mg/kg b.w./day, females: 63 - 250 mg/kg b.w./day), observed
effects included elevated kidney weights and, toward the end of the exposure
period, lower body weights in females in the high-dose group. In a parallel cancer
study with mice (NTP 1994, cited in Reference 29; NTP 1999, cited in Reference
25), skin applications of TEA in acetone (males: 200 – 2000 mg/kg b.w;
females:100 – 1000 mg/kg b.w.) 5 days/week for 2 years resulted in elevated
kidney weights in males at dose levels of 630 mg/kg b.w/day and higher.
In an unpublished study (cited in References 25 and 29) in which rats and
mice were exposed by inhalation to 125 - 2000 mg/m3 TEA in aerosol form
6 hours/day, 5 days/week for a 16-day period, reported effects include reduced
body weights at the highest exposure level, and in rats elevated kidney weights at
exposures of 500 mg/m3 and higher. There were no observed histopathological
changes in kidneys. Effects on the mice included changes in some hematological
parameters (dose levels not given), and females exposed to 1000 mg/m3 or more
had lower thymus and heart weights.
6Various degrees of irritation have been reported after skin application of
TEA. TEA was reported to be non-irritating or mildly irritating in different skin
irritation tests with rabbits (15, 49). Guinea pigs developed skin inflammation
after 2 to 17 skin applications of 8 g undiluted TEA/kg b.w./day (5 days/week,
occlusion) (28). Mice given repeated skin applications for up to 20 weeks,
however, showed no serious indications of chronic irritation (14, 43). In an
unpublished long-term study, TEA in acetone was painted on the skin of mice
and rats (concentrations not given). For the mice (high-dose group), the treatment
resulted in acanthosis and chronic skin inflammation, but not necrosis; and for
the rats, inflammation and sores at the site of application (NTP 1994, cited in
Reference 29; NTP 1999, cited in Reference 25).
TEA has also been tested on animals for allergenic effect on skin. It caused
no sensitization in the Guinea Pig Maximization Test (0/20 animals) and was
classified as a weak allergen (Grade 1) (7).
Several studies have reported that TEA is slightly irritating to the eyes of
rabbits (15, 21, 49). An older study, however, reports that undiluted TEA caused
relatively severe damage to the eyes of rabbits (Grade 5 on a scale of 1 to 10) 18
to 24 hours after application (9).
Mutagenicity
TEA has been tested for mutagenicity/genotoxicity in several short-term tests both
with and without metabolic activation (25). TEA alone yielded negative results in
tests with various strains of bacteria and yeast (S. typhimurium TA98, TA100,
TA1535, TA1537, TA1538; E. coli WP2, WP2try-, WP2uvrA; B. subtilis
TKJ5211uvrA-, H17 rec+/M45rec-; S. cerevisiae JD1). TEA mixed with sodium
nitrite yielded mutagenic effects in test systems with various strains of B. subtilis
without metabolic activation, but negative results when metabolizing systems
were added. TEA without metabolic activation was also negative in in vitro test
systems measuring DNA repair (rat liver cells), sister chromatid exchanges (CHO
cells), chromosome aberrations (rat liver cells, CHO cells, CHL cells) and cell
transformation (hamster embryo cells). TEA induced no sister chromatid ex-
changes or chromosome aberrations in CHO cells when metabolizing systems
were added. There are also a few in vivo tests of TEA. Gene mutations were
not induced by up to 30,000 ppm (equivalent to 30,000 mg/kg) TEA given to
Drosophila either orally or by injection (sex-linked recessive lethal test).
Chromosome damage, expressed as an elevated frequency of micronuclei in red
blood cells, was not observed in mice after skin application of TEA for 13 weeks
(25).
Carcinogenicity
According to the IARC, it is not possible to determine whether TEA is carcino-
genic to either man or experimental animals (25). In its summary assessment TEA
7is placed in Group 3: “not classifiable as to its carcinogenicity to humans.” This
conclusion is based on the following studies:
In a cancer study, mice were given feed pellets containing 0, 0.03% or
0.3% TEA for their entire lives. There was a significant (p<0.05) increase of
lymphomas in females (control 1/36; low-dose group 7/37; high-dose group 9/36),
but no observed increase in males (24). The report contains no information on
lymphoma incidence in historic controls, but Knaak et al. (29) state that the
lymphoma incidence in controls in this study is extremely low. It is also unclear
whether breakdown products were formed when the TEA was heated for pellet
production. In another mouse study, drinking water containing 0, 1% or 2%
(maximum tolerable dose) TEA was given to animals of both sexes for 82 weeks,
and the animals were killed immediately thereafter. No increase in tumor
incidence is reported (30). A study in which rats were given TEA in drinking
water for 2 years also reports no significant increase in tumor incidence (33).
In this study, 0, 1%, or 2% TEA (≈ 525 or 1100 mg/kg b.w./day) was given to
males for 2 years; these concentrations were halved for females from week 69
onward because of a dose-dependent increase in mortality (≈ 910 or 1970 mg/kg
b.w./day initially; ≈ 455 or 985 mg/kg b.w./day after reduction). A positive trend
(p<0.05) was seen for neoplastic nodules/carcinomas in the livers of males and for
sarcomas in the mucous membranes of the uterus and adenomas in the kidneys of
females, when the statistics were adjusted for age. The incidence in the control
group, however, was lower than that in historic controls, and the authors
concluded that TEA was not carcinogenic (29, 33).
In a cancer study in which TEA in acetone was applied to the skin of mice
(males: 0, 200, 630, 2000 mg/kg b.w.; females: 0, 100, 300, 1000 mg/kg b.w.)
5 days/week for 103 weeks, tumors were seen in the livers of both sexes. No
conclusions can be drawn from this observation, however, since the animals had
been infected with Helicobacter hepaticus, a bacterium associated with hepatitis
and in some cases also with higher incidences of liver tumors (17; NTP 1999,
cited in Reference 25; NTP 1994, cited in Reference 29). TEA in acetone applied
to the skin of rats (males: 0, 32, 63 or 125 mg/kg b.w.; females: 0, 63, 125, 250
mg/kg b.w.) 5 days/week for 103 weeks caused no significant increase in tumor
incidence. Males treated with TEA had more severe renal hyperplasias (and
adenomas) than controls, however (NTP 1999, cited in Reference 25; NTP 1994,
cited in Reference 29). In a study with transgenic mice (Tg.AC), no increase of
skin tumors was seen in animals given dermal applications of TEA in acetone (3,
10 or 30 mg per animal per application, ≈120, 400 or 1200 mg/kg b.w.) 5 days/
week for 20 weeks. The animals were killed 6 weeks after the final treatment (43).
No cancer studies of persons exposed only to TEA were found in the literature.
However, there are several epidemiological studies of workers exposed to metal-
working fluids containing ethanol amines either with or without sodium nitrite. A
slight increase of cancers, especially in stomach, esophagus and larynx, has been
discovered in these studies, but since exposures were always mixed it is hardly
8possible to draw from the presented data any conclusions about the
carcinogenicity of TEA (25).
Effects on reproduction
Injection of 1.3 - 10.5 mmol TEA in acetone into chicken eggs had an embryo-
toxic effect (ED50 2.6 mmol/egg), but no significant teratogenic effect (3/110
anomalies vs. 1/100 in acetone-treated control eggs) (31).
Unpublished studies (cited in References 25 and 29) report no effects on
mating, fertility, growth or survival of offspring in rats given daily skin appli-
cations of 500 mg TEA (in acetone) /kg b.w., and no effects on reproduction in
mice given skin applications of 2 g TEA/kg b.w./day. No significant effects on
sperm (motility, morphology, number) or changes in duration of estrus cycle were
reported in another unpublished study (NTP 1999, cited in Reference 25) in which
rats and mice received skin application of up to 2 (rats) or 4 (mice) g TEA/kg
b.w./day for 13 weeks.
Dose-effect / dose-response relationships
There are no data on which to base a dose-effect or dose-response relationship
for occupational exposure to TEA. Dose-effect relationships observed in animal
experiments are summarized in Table 2. A brief review mentions some unpub-
lished data indicating an effect on kidney weight after inhalation exposure at
doses that may possibly be lower than those in Table 2.
Conclusions
In general, there are little or no data on health effects of inhalation exposure to
TEA, for either humans or animals. However, two cases of asthma, diagnosed as
work-related and caused by TEA, have been reported.
The critical effect in animal studies with repeated oral administration of TEA is
effects on the kidneys. A few cases of allergic contact eczema due to skin contact
with TEA have been reported, but the allergenic potency of TEA is probably low.
Animal studies have shown that skin uptake can be quite high.
9Table 2. Dose-effect relationships observed in laboratory animals exposed to TEA.
Exposure Species Effects Ref.
2150 mg/kg b.w./day
dermal
3 days/week
13 weeks
Mouse Mild skin irritation, significant reduction
(p<0.05) in lymphocyte counts (males),
significant reduction (p<0.05) of alkaline
phosphatases in serum (males)
14
2% in drinking water,
2 years
(≈ males 1100 mg/kg
b.w./day;
females: 1970 and later
985 mg/kg b.w./day)***
Rat Females: increased mortality, pyelonephritis,
hydronephrosis
Both sexes: impaired growth, elevated kidney
weights, chronic nephropathy, mineralization
of renal papillae and “nodular hyperplasia of
the pelvic mucosa”
29, 33
800 mg/kg b.w./day
per os
60 or 120 days
Rat,
Guinea pig
Rat: histopathological changes in kidneys* and
liver
Guinea pig: histopathological changes in
kidneys and liver**
28
730 mg/kg b.w./day
per os
90 days
Rat Deaths; histopathological changes in liver,
kidneys, spleen and/or testes
42
1% in drinking water
2 years
(≈ males: 525 mg/kg b.w./day;
females: 910 and later
455 mg/kg b.w./day)***
Rat Females: Increased mortality, pyelonephritis,
hydronephrosis, chronic nephropathy
Both sexes: Poor growth, elevated kidney
weights, mineralization of renal papillae
29, 33
400 mg/kg b.w./day
per os
60 or 120 days
Rat,
Guinea pig
Rat: histopathological changes in kidneys* and
liver*
Guinea pig: histopathological changes in
kidneys*
28
200 mg/kg b.w./day
per os
60 or 120 days
Rat,
Guinea pig
Histopathological changes in kidneys** 28
170 mg/kg b.w./day
per os
90 days
Rat Changes in liver or kidney weights 42
* observed after 60 days
**observed after 120 days
*** due to high mortality the dose for females in both dose groups was halved from week 69
onward
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Consensus Report for Diesel Exhaust
December 4, 2002
This Report is a review of the risks of occupational exposure to diesel exhaust,
with emphasis on those identified in studies with human subjects. Diesel exhaust
also occurs in the general environment as a component of a complex mixture of
air pollutants of diverse origin (combustion products from heating, particles and
gases from remote sources, dust etc.). There are several studies on the health
effects of air pollutants in the general environment, but these studies are given
cursory attention in this document since diesel exhaust is only a part of general
air pollution.
Diesel exhausts are extremely complex mixtures of substances, some of which
– especially nitrogen dioxide and elemental carbon – have been used as indicators
of exposure to diesel exhaust. In this report we have paid particular attention to
the degree of association between indicator substances and effects on health. The
Report is based on a survey published in 1993 (4) and on subsequently published
literature. In many cases reference is made primarily to critical reviews judged to
cover the relevant literature.
Physical and chemical characteristics
Diesel exhaust is produced by the combustion of diesel oil, which yields a
complex mixture of compounds in both gas and particle form. The exact
composition varies with fuel type, engine model and tuning, driving conditions,
load, exhaust cleaning methods etc. The gas phase includes carbon dioxide,
carbon monoxide, nitrous oxides, sulfur oxides, aldehydes and hydrocarbons –
both volatile hydrocarbons such as methane and ethylene and heavier poly-
aromatic hydrocarbons (PAH). The composition of some types of diesel fuel
and examples of the variation in composition of the exhausts from these fuels
are tabulated in Beije (4).
Both density and volatility affect the relationship between the composition of
the diesel fuel and that of the exhaust. The relationship between aromatic and
polyaromatic hydrocarbons and sulfur in the fuel and the chemical composition
of the exhaust has been explored in a large number of studies. The importance of
sulfur in particle formation has led to the introduction of MK1 (= miljöklass 1,
environmental class 1), a diesel fuel with low sulfur content. Aromatic hydro-
carbons in the diesel fuel also make a large contribution to particle formation.
Today nearly all diesel fuel used in Sweden is MK1. In 2001, 98% of all diesel
fuel sold was MK1, and only 2% was MK3. This can be compared with 1993,
when only 20% of all diesel fuel sold was MK1, 57% was MK2 and 23% MK3
(56). Some of the requirements for these fuel classes are listed in Table 1.
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Table 1. Swedish standards for environmental classification (MK) of diesel fuel
(chemical content) (56).
Component Measure MK1 MK2 MK3
Aromatic hydrocarbons (max. volume) % 5 20 -
PAH (max. volume) % Not
detectable
0.1 -
PAH (max. mass) % - - 11
Sulfur mg/kg 10 50 350
The composition of diesel exhaust is closely related to the type of engine.
Regulations in many countries stipulate that vehicle manufacturers must have at
least one vehicle of each engine and model type emission-tested. The emissions
covered by regulations are usually nitrous oxides (NOX), carbon monoxide (CO),
total hydrocarbons (THC) and particles. The tests are made under a number of
specified driving conditions known to affect emission levels. Different protocols
have been used in different countries and for different types of vehicles, which
makes it difficult to compare data from different studies. There is little infor-
mation on emissions from vehicles that have been in use for several years. More-
over, the vehicles that are tested are not always representative – for example,
about a third of the heavy vehicles tested in the USA are mass-transit buses, which
in 1998 accounted for only about 5% of the heavy vehicles on the road (63).
Yanowitz et al. (63) tracked changes in emissions from diesel vehicles tested
during the 1976 – 1998 period. There were clear reductions in particles (PM),
carbon monoxide and hydrocarbons, whereas NOX levels declined very little. The
authors also point out that some manufacturers design their engines to produce
low emissions under the test conditions, which means that during actual use the
vehicle’s emissions might be higher than they would have been if the engines had
been designed for optimum performance under driving conditions.
Particle emissions can be greatly reduced (at least in terms of total mass) by
various exhaust purification systems, most commonly catalytic treatment and
various types of particle filters. A general problem with engine tuning, fuel
modifications and other measures taken to reduce particles in diesel exhaust
is that they often increase the emission of NOX and vice versa.
Indicators and their measurement
Particles
Particles that can be inhaled are usually < 10 µm in diameter. These particles,
often called PM10, can be divided by size into three groups:
1. Ultra-fine particles smaller than 0.1 µm. Formed during combustion (e.g. in
diesel engines) and from chemical substances in the gas phase.
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2. Particles 0.1 - 2.5 µm. Formed by coagulation of ultra-fine particles and by
adsorption of gas-phase material onto existing particles. These particles can
remain suspended in the air for a long time.
3. Particles larger than 2.5 µm. Includes airborne dust and dirt. Though
relatively few in number, these account for a large amount of the total PM10
mass.
Categories 1 and 2 are sometimes referred to together as PM2.5.
Ultra-fine particles with diameters of 5 to 50 nm account for 50 - 90% of the
total number of particles in diesel exhaust, but only 1 – 20% of the total mass
(16). However, small particles often join together to form larger ones, which
means that the size distribution in a sample may depend partly on when the
sample is taken (in the exhaust pipe or after the exhaust has been in the air for a
few minutes). The size distribution of particles in diesel exhaust may thus vary
somewhat because of differences in sampling conditions.
A problem that has increasingly come into focus with regard to measuring
particle emissions from diesel engines is the difficulty of differentiating diesel
particles from other particles.
Many publications in recent years have presented studies of elemental carbon
(EC) as a measure of particle emissions from diesel vehicles and thus as an
indicator of diesel exhaust. Of other methods used for determination of particles in
diesel exhaust the most common are gravimetric, for determination of the mass of
sub-micrometer particles and respirable combustible dust (RCD). In mines in the
USA, diesel particles have usually been measured as diesel particulate matter
(DPM), separated by size during sampling and analyzed with gravimetric
methods, while in Canada particles are usually measured as RCD. Both of these
methods, however, are vulnerable to interference from particles produced by other
forms of combustion, and neither method is sensitive enough to measure personal
exposures unless concentrations are high.
Elemental carbon (EC) is determined by collecting diesel exhaust particles on a
quartz filter, followed by a two-step analysis in which organic carbon (OC) is first
removed and the amount of elemental carbon is then determined (40).
The EC method, unlike other methods used for particles, is said to be specific
for diesel exhaust. However, the proportion of elemental carbon in diesel particles
can vary, which makes it difficult to directly extrapolate the amount of EC to a
measure of the total mass of particles smaller than 1 µm (40). Studies have shown
that interference from tobacco smoke is negligible (5, 64), as is interference from
spores, pollen and other particles from plants (5). In coal mines there is a risk of
interference from the coal being mined, although Birch and Cary (5) maintain that
the EC method can be used in this environment also, provided that a suitable
impacter is used in sampling. In an inter-laboratory calibration study in which
ten laboratories analyzed EC, there was a pooled relative standard deviation of
52.3% (5).
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NOX
NOX is by tradition the primary indicator for diesel exhaust. Although it is often
measured as NO2, it is emitted primarily as NO. In oxidative environments NO
is oxidated to NO2 , and in environments such as mines and bus garages where
emissions remain in the air and mix with substances such as ozone, a large part
of the total amount of NOX is NO2. In other environments such as tunnels for
vehicle traffic, where most of the emissions in the air are of recent origin, much
of the NOX occurs as NO (18).
Some comparative studies of air concentrations of EC, RCD and NOX (or NO2)
in environments exposed to diesel exhaust have been published. The studies show
a correlation between EC and RCD, although the proportions may vary (RCD is
10 to 50 times higher than EC). Correlations between nitrous oxides and EC or
RCD have been weak in these studies (61), which means that a measure of EC can
not be translated to a measure of NOX (and vice versa). In some studies, however,
several indicator substances have been measured simultaneously.
There has been some interest in profiling the polyaromatic hydrocarbons (PAH)
associated with particles in diesel exhaust, since biological experiments have
shown effects of these substances (55, 62). In environmental monitoring there
is also an interest in using PAH patterns to differentiate emission sources such
as biofuel and diesel fuel.
Occurrence and exposure
In 2001, refineries in Sweden produced/sold 3,556,000 m3 of diesel fuel. This is
19% more than in 1992. Comparable figures from other Nordic countries are
3,015,000 m3 for Denmark, a 37% increase over 1992; 3,642,000 m3 for Norway,
more than twice as much as in 1992; and 2,159,000 m3 for Finland, 48% more
than in 1993.
Results of monitoring for various diesel exhaust components and/or exposure
indicators have been reported for railroad workers, vehicle mechanics, forklift
operators, miners, tunnel repairmen and workers on ro-ro freighters and in bus
garages, vehicle inspection stations etc. The highest concentrations are reported
in mines that use diesel equipment (Table 2).
Interest in particles as indicators of exposure is clearly reflected in the literature
giving exposure data for diesel exhausts. Most of the articles published in the past
decade report only particle measurements of various types. A few of these studies,
published in the past six years, are summarized in Table 2.
Occupational exposure should be regarded in the perspective of exposure of the
general public. In the USA, the EPA has estimated the average exposure to diesel
particles (measured as DPM) to be 0.6 µg/m3 for the entire population: 0.3 µg/m3
in the country and 0.8 µg/m3 in cities (figures are from 1996) (16). The EPA
document also cites several studies in which elemental carbon was measured.
Concentrations as high as 40 µg/m3 have been measured on automobile freeways
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Table 2. Exposure to diesel exhaust at various workplaces.
Workplace/occupation Country Monitored
component
Concentration
(range)
Ref.
Ambulance depot USA Respirable dust
EC
118 (70-180) µg/m3
33 (18-42) µg/m3
19
Ro-ro freighters USA Respirable dust
EC
198 (32-920) µg/m3
37 (7-111) µg/m3
19
Railroad worker USA
Canada
Respirable dust
EC
EC
190 (32-902) µg/m3
17 (7-50) µg/m3
7 (2-14) µg/m3
19
61
Bus garage USA Respirable dust
EC
224 (70-980) µg/m3
31 (7-217) µg/m3
19
Firefighter USA EC 20-79 µg/m3 5
Firehouse employee USA EC 4-52 µg/m3 5
Airport personnel USA EC 7-15 µg/m3 5
Public transportation
worker
USA EC 15-98 µg/m3 5
Vehicle inspection USA Respirable dust
EC
149 (90-220) µg/m3
11 (7-31) µg/m3
19
Truck driver USA Respirable dust
EC
369 (79-1356) µg/m3
66 (7-403) µg/m3
19
Tunnel excavator Norway Total dust
Respirable dust
EC
NO2
5.5 (0.2-56) mg/m3
1.7 (0.03-9.3) mg/m3
220 (63-580) µg/m3
1.5 (0.06-5.5) mg/m3
1
Coal mines, diesel
equipment without
exhaust treatment
USA DPM Mine A 0.85 mg/m3
Mine B 2.1 mg/m3
Mine C 1.3 mg/m3
21
Coal mines, diesel
equipment with
exhaust treatment
USA DPM Mine A 0.2 mg/m3
Mine B 1.2 mg/m3
Mine C 0.1 mg/m3
Mine D 0.1 mg/m3
21
Coal mines, exhaust
treatment not reported
Australia DPM 0.01-0.64 mg/m3 44
Other mines, exhaust
treatment not reported
USA
USA
Germany
DPM
DPM
EC
Respirable dust
Salt 0.4-0.7 mg/m3
Lead/zinc 0.3-1.1 mg/m3
Limestone 0.3 mg/m3
Potash 0.6-1.6 mg/m3
Potash 0.1-1.0 mg/m3
Potash 190 (17-606)
µg/m3
Potash 0.038-1.28 mg/m3
21
57
59
Iron mine, diesel
equipment with
exhaust treatment
Sweden EC 29 (5-81) µg/m3 31
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in the USA. In a study of EC concentrations in Dutch schools, levels of 1.1 –
6.3 µg/m3 (n = 23) were measured in schools near highways, whereas in schools
over 400 meters from highways the levels were 0.8 – 2.1 µg/m3 (n = 8) (16).
Kinney et al. (30) used personal monitors to measure EC levels on the sidewalks
in Harlem (USA), and obtained values in the range 1.5 – 6 µg/m3. Zaebst et al.
(64) measured elemental carbon in urban environments in the USA. On highways
the average was 2.5 µg/m3 (n = 21) and in residential areas 1.1 µg/m3 (n = 23).
Uptake, biotransformation, excretion
Diesel exhaust is a complex mixture of gases and particles. For nitrogen dioxide,
for example, calculated uptake is 80 to 90 % (33). In an experiment with healthy
subjects it was found that 23% of the particles from diesel exhaust were deposited
in the lungs, but there is reason to believe that deposition rates vary considerably
(4). Liberation of substances bound to the particles in the lungs is probably also
subject to large variation, depending on what substances are involved and where
the particle is deposited. A major subject of study has been benzo-a-pyrene (BaP).
Theoretical calculations indicate that retention of BaP might be lower in the
bronchi than in the more peripheral parts of the lungs (4). BaP disappears from the
lungs of laboratory animals in a fast phase (<1 hour) and a slow phase (18 days).
The metabolism of BaP has been extensively studied (35).
The biotransformation and excretion of BaP from diesel exhaust have been
studied in animal experiments. In human studies, non-smoking subjects who
work in garages and vehicle repair shops have higher excretion of 1-hydroxy-
pyrene in urine and a greater amount of DNA adducts (both total and aromatic)
than controls (24, 26, 37).
A problem with these studies is determining the extent to which excretion of
1-hydroxypyrene is also due to skin uptake. Persons exposed to diesel exhaust
while working in garages and repair shops can be expected to get motor oil and
other substances containing PAH on their hands.
Toxic effects
The toxic effects of diesel exhaust that have received the most attention are its
effects on the lungs and respiratory passages, both acute and chronic, and the
increased risk of various forms of cancer. Although is not clear just what
substances (or substance) in diesel exhaust are responsible for its toxic effects,
particles or NO2 are often used as indicators. Diesel exhaust comprises a not
insignificant proportion of air pollutants in urban areas. Studies from several
parts of the world, including Sweden, have shown that variations in the airborne
particle concentration in urban areas not only affect the health of asthmatics
(frequency and severity of symptoms) but also are correlated to variations in
mortality (16). Mortality from heart disease has also been shown to increase.
Other studies have shown that this type of pollution affects heart rhythm in
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patients with severe heart disease. Further, some studies have demonstrated a
correlation between air pollutants and indicators of inflammation such as acute-
phase proteins and fibrinogen. Since it is known that persons with higher levels of
such indicators have an elevated risk of developing heart/circulatory diseases, it
has been proposed that some health effects of air pollution are caused via an
inflammatory reaction. Studies from the USA have also demonstrated correlations
between the average levels of air pollutants in urban areas and mortality and
occurrence of cancer (16). In these studies, particles (e.g. PM10 or PM2.5, defined
above under Indicators) or NO2 are often used as exposure indicators. Since both
particles and NO2 also have sources other than diesel exhaust, it is not possible to
determine the degree to which diesel exhaust is implicated in these health effects.
Studies that specifically attempt to connect diesel exhaust with effects on health
are described below.
Human studies – controlled exposure
Effects of diesel exhaust
The cellular and biochemical effects on respiratory passages of short-term
exposure to diesel exhaust have been studied in exposure experiments. These are
made possible by accurate exposure and monitoring equipment that can show that
the levels of particles and soluble components are the same as those in the exhaust
pipe (47).
One study describes symptoms affecting the eyes and nose, as well as increased
airway resistance, after 1 hour of exposure to diesel exhaust at a particle
concentration of 300 µg/m3 (PM10) and an NO2 concentration of 2.9 mg/m3 (46).
Several studies have been made using bronchoalveolar lavage (BAL) and
analysis of tissue samples from respiratory passages. BAL showed elevated
numbers of neutrophilic granulocytes in healthy persons 6 to 24 hours after 1 hour
of exposure to diesel exhaust with a particle concentration of 300 µg/m3 (PM10)
and an NO2 concentration of 2.9 mg/m3 (45, 48, 49). Reduced phagocyte activity
was also noted in alveolar macrophages (45, 48). Tissue samples taken from
mucous membranes in the airways of healthy subjects six hours after exposure
to diesel exhaust (300 µg/m3, PM10) showed clear inflammatory changes, with
elevated levels of adhesion molecules, inflammatory cells and cytokines (49, 50).
There were also systemic effects, including higher numbers of neutrophilic
granulocytes and thrombocytes in peripheral blood.
In a recent study, both healthy subjects and subjects with mild asthma were
exposed to a low concentration of diesel exhaust (PM10 108 µg/m3, NO2 0.36
mg/m3) for 2 hours. In the healthy subjects the effects were very small – only an
increase in the number of neutrophilic granulocytes – and the only significant
effect in the asthmatics was an increase in bronchial epithelium of IL-10, a
cytokine often associated with bronchial reactivity (25).
A primary indication of asthma is that inhalation of irritants causes the airways
to contract. In asthmatics this reaction, called bronchial reactivity, is seen at much
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lower doses than in healthy subjects. This is the characteristic symptom of asthma.
In a recently published study, increased bronchial reactivity was seen in a group
of asthmatics 24 hours after one hour of exposure to diesel exhaust (PM10, 300
µg/m3) (41). These asthmatics had moderately severe asthma that required
treatment with inhalation steroids (800-1200 µg/day). These observations of
increased bronchial reactivity may help to explain epidemiological data indicating
that air pollution with higher particulate content results in more severe symptoms
in asthmatics.
In another study, subjects with mild allergic asthma were exposed for 30
minutes to exhaust in a highway tunnel. Since the exposure came from traffic,
the air also contained other pollutants such as dust from road and tire wear. No
attempt was made to identify the origin of the particles. The average concentration
of NO2 was 313 µg/m3, PM10 was 170 µg/m3, and PM2.5 was 95 µg/m3. Four
hours later a provocation test was made with a low dose of an inhaled allergen
(birch pollen). After the allergen exposure, the subjects exposed to the tunnel
concentrations of NO2 (300 µg/m3 or higher) developed both significantly higher
early reaction (measured as increased airway resistance) and late reaction, with
lower FEV1 3 to 10 hours after the allergen inhalation. Moreover, subjects
exposed to PM2.5 in concentration > 100 µg/m3 had slightly greater early reactions
than controls (58). This study showed that exposure to environments containing
exhaust and dust from road traffic significantly enhances the asthmatic reaction to
allergen inhalation.
Effects of NO2
Several studies have been made in which subjects in an exposure chamber were
exposed to NO2 alone in concentrations ranging from 1.1 to 9 mg/m3, after which
BAL and mucous membrane biopsies were used to quantify inflammation
indicators (7, 8, 22, 23, 51, 52, 53, 54). The heaviest exposure was 3.6 mg/m3 for
4 hours on 4 consecutive days (8). It is interesting to note that these inflammatory
changes were much smaller than those caused by diesel exhaust, even when the
exposure dose of NO2 was many times higher. NO2 is therefore assumed to play
a subordinate role in inflammatory reactions to diesel exhaust exposure.
Effects of particles
A number of studies have been made to assess the allergenic potential of the
particles in diesel exhaust. When 0.30 mg of diesel exhaust particles were
deposited in the noses of healthy subjects, levels of IgE and IgE-secreting cells
were higher 1 to 4 days after the treatment. This dose was estimated to be
equivalent to 24 hours of inhaling outdoor air in Los Angeles, California (14).
Amounts of mRNA, including mRNA coding for cytokines that stimulate IgE
production, increased in cells from nasal lavage after 0.15 mg diesel exhaust
particles had been deposited in the noses of healthy subjects (12). This can
contribute to increased local IgE production. The role of diesel particles as
adjuvants to allergens has also been examined. An allergen in combination with
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diesel particles significantly increased the expression of mRNA for TH2 cytokines
and inhibited the formation of γ-interferon, and also increased the production of
antigen-specific IgE (13).These data indicate that diesel exhaust particles can
increase B-cell differentiation and raise IgE production. Diesel exhaust particles
have also been found to enhance sensitization on exposure to new allergens.
When an antigen from keyhole limpets (a mollusk) was used in sensitization tests
together with either diesel exhaust particles or a placebo, the exhaust particles
caused a much stronger sensitization and allergic reaction (15). The allergen was
placed on the nasal mucosa of healthy, previously unsensitized subjects with or
without simultaneous exposure to diesel exhaust particles.
Animal studies
In general, it is difficult to extrapolate these data to human exposures because
much higher concentrations of diesel exhaust are used in animal experiments.
In long-term studies, rats exposed to a particle concentration of 1000 µg/m3 for
6 months had indications of local inflammation, epithelium proliferation, fibrosis
and emphysema development (29). No changes were seen in the lungs of cats
exposed to 6000 µg/m3 diesel particles for more than a year, although at higher
concentrations (6340-11,700 µg/m3) and NO2 (4.9-5.2 mg/m3) there were morpho-
logical changes in the form of peribronchial fibrosis and elevated numbers of
inflammatory cells and fibroblasts, indicating a pro-fibrotic effect of long-term
exposure to diesel exhaust (27). In a comparative study, cynomolgus monkeys and
rats were exposed to 2000 µg/m3 diesel exhaust particles for 2 years: it was found
that the monkeys retained more particles but, unlike the rats, showed no indica-
tions of inflammation or fibrosis (38, 39).
In vitro studies
Studies have been made with transformed cell lines developed from human
bronchial epithelium, and the results generally confirm the results of the in vivo
studies. Increased synthesis and liberation of inflammation-generating cytokines
such as IL-1, IL-6, IL-8, GM-CSF, as well as increased liberation of the adhesion
molecule s-ICAM-1, have been reported (2, 9, 11). Cells from asthmatics are
reported to be more sensitive to low concentrations of particles from diesel
exhaust than cells from healthy persons with regard to production of IL-8, GM-
CSF and sICAM-1 (3). It has also been noted that a high dose of DEP reduces the
production of cytokines IL-8 and RANTES in cells from asthmatics in vitro (3).
Human epithelial cells have been found to produce cytokines involved in allergic
reactions and allergy development after they have been exposed to DEP (43),
which is in accord with the above-described reaction to experimental instillation
of DEP in the nose (12, 13, 14). Further, isolated human B-cells can increase their
production of IgE after exposure to particles from diesel exhaust (60).
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Mutagenicity, carcinogenicity
Mutagenicity
Diesel exhaust contains many substances, including several with known
mutagenic effect, such as various PAHs and nitro-PAH. Many mutagenicity tests
have been made with diesel exhaust or particles from diesel exhaust, with positive
results. Filtered diesel exhaust has also shown mutagenic activity in vitro.
When mice and rats were exposed to diesel exhaust in long-term studies, the
mice developed more micronuclei but not in the rats. No dominant-lethal effect
was seen in rats exposed to diesel exhaust. Sex-linked recessive lethal mutations
were not found in Drosophila exposed to diesel exhaust for 8 hours (concentration
expressed as 2.2 mg soot/m3). Elevated levels of DNA adducts have been
observed in laboratory animals exposed to diesel exhaust (4).
In a small Swedish study a non-significant increase of chromosome aberrations
(CA), but no increase of sister chromatid exchanges (SCE), was found in truck
drivers (N = 12) (17). In another Swedish study, no increase of CA was seen
among miners exposed to diesel exhaust when they were compared to controls
(42). Studies of persons occupationally exposed to diesel exhaust have revealed
no increase in urine mutagenicity (4).
Carcinogenicity
Animal data
Different species have shown different responses in cancer tests with diesel
exhaust.
Studies with mice have had varying results, and do not clearly indicate a
carcinogenic response. Studies with hamsters have been negative (16). Studies
with rats have clearly shown a dose-dependent carcinogenic response (4). A study
with CD-1 mice, under experimental conditions known to cause a dose-dependent
increase of lung tumors in rats, yielded no lung tumor increase in the mice (34). In
the rat studies, however, the tumor increase occurred only at such high doses that
the normal clearing system in the lungs was overloaded. In general, the rats that
developed tumors were exposed to particle concentrations around 2.5 mg/m3 (16).
Rats exposed to similar particle concentrations of soot or titanium dioxide also
have elevated incidences of lung tumors. Rats exposed to filtered (particle-free)
diesel exhaust under the same conditions showed no statistically significant
increase in lung tumors (16).
Human data
There are many epidemiological studies in which the possibility of a connection
between cancer and occupational exposure to diesel exhaust has been explored.
Groups commonly studied are drivers – especially drivers of trucks, construction
equipment or diesel locomotives – and miners. There are several compilations and
meta-analyses of these studies. In these analyses, the relative cancer risk for
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drivers of trucks and diesel locomotives has been around 1.5; the results vary
somewhat depending on the studies included and the treatment of confounding
factors. The confounding factor receiving by far the most attention is smoking, but
few studies provide adequate information on smoking habits. Other confounding
factors are possible simultaneous exposure to other carcinogens such as asbestos.
Estimates of exposure to diesel exhaust are also a weakness of most of the studies.
Occupation is frequently used, and sometimes there are exposure estimates based
on job category. The greatest hope of obtaining reliable exposure data is in studies
of miners, especially those who work in mines where there is little radon or
quartz. The levels of diesel exhaust are relatively high in mines (compared to city
traffic, for example). The inadequacy of data in these studies is due mostly to the
fact that diesel equipment was introduced fairly recently (often during the 1960s)
and there has not been enough time to reveal a low increase in statistical risk.
Common to all the compilations of epidemiological studies on the risk of lung
cancer due to exposure to diesel exhaust is that they support the suspicion that
there is a connection. Most, however, express some reservation due to the
occurrence of confounding factors. Other forms of cancer that have been tenta-
tively connected to exposure to diesel exhaust are bladder cancer, cancer in
lymphoid tissue and blood-forming organs, and prostate cancer (16). These
connections, however, are not unequivocally supported in the literature and
are not reviewed more fully here. A compilation of the conclusions in surveys
of a connection between lung cancer and exposure to diesel exhaust is given in
Table 3.
Table 3. Assessments of relationships between exposure to diesel exhaust and lung
cancer given in meta-analyses and surveys of epidemiological studies.
Reference Conclusion
IARC 1989 (28) “limited ”
California EPA 1998 (10) “consistent evidence for a causal association”
Bhatia et al. 1998 (6) ”This meta-analysis supports a causal association between
increased risks for lung cancer and exposure to diesel
exhaust.”
Lipsett & Campleman 1999 (32) “This meta-analysis provides quantitative evidence
consistent with several prior reviews, which have
concluded that the epidemiological evidence supports
a causal relationship between occupational exposure to
diesel exhaust and lung cancer.”
NTP 2000 (36) “elevated lung cancer in occupationally exposed groups.”
EPA 2002 (16) “judged to be strong but less than sufficient to satisfy the
criteria for a “known” human carcinogen”
24
Indicators of cancer risk
The epidemiological studies do not contain exposure data that is good enough to
allow identification of the component or components in diesel exhaust that would
be the best indicator(s) of risk (NO2, certain types of particles, etc.).
Swedish conditions are reflected in a case-control study from Stockholm
county, in which the risk of lung cancer was examined for 1042 cases and 2364
controls (20). Exposure to diesel exhaust and other substances was based on
information on occupation, which was then classified blind by an occupational
hygienist for case/control status: 180 of the cases and 312 controls were judged to
have occupational exposure to diesel exhaust. There was no clear connection to
intensity of exposure to diesel exhaust, defined as the highest exposure ever
during a year. However, there was a statistically significant correlation between
estimated cumulative dose and risk of lung cancer when data were adjusted
for tobacco smoking, exposure to radon in the home, asbestos exposure and
environmental exposure to nitrogen dioxide and other combustion products. The
relative risk for an increase of the cumulative dose with 1 mg/year/m3 of diesel
fumes measured as NO2 was 1.09 (95% CI: 1.02 – 1.16).
Animal studies have shown that both “pure” carbon particles and mixtures of
polyaromatic hydrocarbons can increase the incidence of lung cancer in rats (16).
Reproductive effects
Studies with monkeys have not shown effects on spermatogenesis even at
relatively high concentrations (2.0 mg/m3 DEP measured as soot) (4). No
studies on teratogenicity were found.
Dose-effect / dose-response relationships
Controlled experiments with human subjects indicate that effects of short-term
exposure to diesel exhaust appear in the airways when the particle content is about
0.1 mg/m3 and the NO2 level is about 0.4 mg/m3 (see Table 4). With one hour of
exposure to exhaust at an NO2 level of 2 to 3 mg/m3, healthy subjects developed
symptoms involving the mucous membranes of eyes and respiratory passages. In
persons with asthma severe enough to require treatment with steroids, bronchial
reactions (measured as bronchial hyperreactivity) appeared at about 2 mg/m3
nitrogen dioxide. In these studies the exposure to elemental carbon was not
measured, and there are no similar studies in which carbon was used as an
indicator of exposure to diesel exhaust.
Experimental studies with rats and other small rodents indicate that there are
large inter-species differences in susceptibility to lung cancer from diesel exhaust.
Studies with rats indicate also that there is probably a threshold dose below which
there is no risk. No animal study, however, has been judged by the EPA to be
strong enough to determine whether there is a threshold for animals (16).
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Table 4. Dose-response relationships observed in people experimentally exposed to
diesel exhaust for brief periods.
Exposed group Particle
concentration
NO2
(mg/m3)
Time Result   Ref.
Healthy
n=8
4.3x106/cm3
(≈300 µg/m3 )
2.7 1 hour Symptoms in mucous
membranes of eyes and
nose
47
Healthy
n=8
4.3x106/cm3
(≈300 µg/m3 )
2.7 1 hour Inflammation, inhibition
of macrophage
phagocytosis in BAL
48
Healthy
n=12
2.6 x106/cm3 3.4 1 hour Increased bronchial
resistance, symptoms
involving eyes and nose
46
Healthy
n=10
2.6 x106/cm3 2.3 1 hour Inflammation, inhibition
of macrophage
phagocytosis in BAL
45
Healthy
n=15
300 µg/m3
(4.3x106/cm3 )
2.9 1 hour Indications of
inflammation in BAL and
biopsies of bronchial
mucosa. Systemic effects
with increased neutrophils
and thrombocytosis in
peripheral blood
49
Heallthy
n=15
300 µg/m3
(4.3x106/cm3 )
2.9 1 hour Elevated mRNA
expression for IL-8 in
BAL and biopsies of
bronchial mucosa.
Increase of cytokines in
bronchial mucosa
50
Asthmatics treated
with steroid
inhalation,
800-1200 µg/day.
n=14
300 µg/m3 2.2 1 hour Doubling of bronchial
hyperreactivity
41
Healthy
n=25
Asthmatics with
mild asthma,
treated only with
bronchodilators
n=15
108 µg/m3 0.36 2 hours Healthy: Slight
indications of
inflammation in
BAL and biopsies of
bronchial mucosa.
Asthmatic: No acute
inflammation, but
increase of cytokine
(IL-10), which may
eventually make the
asthma more severe
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In addition, epidemiological studies of persons who are probably exposed to
considerably lower levels than laboratory rats raise strong suspicions of a
correlation between lung cancer and exposure to diesel exhaust.
Conclusions
The critical effect of exposure to diesel exhaust is irritation and inflammation
of respiratory passages. Slight inflammatory reactions in respiratory passages
have been observed after brief (2-hour) exposure to exhaust levels at which the
measured amount of nitrogen dioxide was about 0.4 mg/m3 and particle content
about 0.1 mg/m3. Clinical effects such as irritation in healthy subjects and
increased bronchial reactivity in asthmatics appeared under similar exposure
conditions at an NO2 level of about 2 mg/m3 and a particle level of 0.3 mg/m3
(measured as PM10). There are no studies indicating whether elemental carbon
can be used as an exposure indicator for such health effects of diesel exhaust.
Occupational exposure to diesel exhaust can increase the risk of lung cancer.
This statement is based primarily on epidemiological studies, which, however,
are unable to clarify the size of the risk in relation to amount of exposure. It is
possible that the increase in risk that has been observed is due to other factors.
Neither epidemiological studies nor animal experiments have been able to
determine which components in diesel exhaust are the best indicators to use
for estimating such risks.
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Consensus Report for Cadmium
February 5, 2003
This Report is based primarily on a recently published critical review of the
literature (30) and subsequently published articles, but some data have also been
drawn from earlier surveys (44, 70). The Criteria Group has previously published
Consensus Reports for cadmium, most recently in 1992 (36); this document will
therefore focus primarily on the subsequently published material.
Chemical and physical data. Occurrence
Formula: Cd
CAS No.: 7440-43-9
Atomic weight: 112.4
Atomic number: 48
Density: 8.6 g/cm3
Melting point: 321 °C
Boiling point: 765 °C
Conversion factors: 1 µg/l = 8.9 nmol/l
1 µmol/l = 112 µg/l
1µg/g creatinine = 1µmol/mol creatinine =
1 nmol/mmol creatinine
1 mmol/kg = 112 mg/kg
Cadmium is one of the heavy metals (usually defined as metals with a density
higher than 5 g/cm3). It occurs naturally in ores together with zinc, lead and
copper. Cadmium compounds are used as pigments (830 tons/year), in alloys and
batteries (about 4200 tons/year), and as stabilizers in plastics (mostly stearate in
PVC products); annual use within the EU dropped from about 270 tons in 1997 to
30 tons in 2000 (12). Over 90% of the cadmium used in Sweden is in rechargeable
nickel-cadmium (NiCd) batteries (Swedish National Chemicals Inspectorate,
1996). The National Swedish Environment Protection Board estimates that 143
tons of NiCd batteries were collected for recycling in the year 2000. Metallic
cadmium has been used mostly as a corrosion inhibitor (cadmium plating).
Cadmium also occurs as a contaminant in phosphate fertilizers. Cadmium in
cadmium compounds has the oxidation state +II. Of the cadmium compounds,
acetate, chloride and sulfate are readily soluble in water and oxide and sulfide
much less soluble. Organic salts of cadmium (e.g. stearate) have fairly low
solubility.
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In Sweden, occupational exposure to cadmium occurs almost exclusively in
battery production. Handling and recycling of scrap metal containing cadmium
may also involve some exposure, but the extent of any such exposure would be
extremely difficult to estimate. Silver solder containing cadmium is probably still
used to a small extent. Air concentrations in Swedish workplaces are probably
almost always below the limit set by the National Board of Occupational Safety
and Health (50 µg/m3 total dust; AFS 2000:3).
Uptake, biotransformation, excretion
Occupational exposure to cadmium is primarily via inhalation, although there
may also be some uptake via the digestive tract (e.g. if lunch is eaten at the work
station) (1). It should be mentioned that cigarette smoke is the primary source of
cadmium exposure for smokers who are not occupationally exposed, and that
tobacco smoke in ambient air may be a source of some cadmium exposure (18).
For non-smokers, most environmental exposure is via the digestive tract.
Uptake of inhaled cadmium is between 10 and 50 percent, depending mostly
on particle size (respirable particles < 5 µm) and solubility (chemical form) (70).
Absorption from the digestive tract is much lower, on the order of a few percent
(5, 70).
Experimental studies have shown that cadmium absorbed after relatively high
single doses binds to high-molecular proteins in the blood (such as albumin) and
is transported to the liver, where it is bound to metallothioneine (MT) and then
re-distributed to other tissues and organs (44). In contrast to albumin-bound
cadmium, the Cd-MT complex is filtered through the renal glomeruli and resorbed
in the tubuli. The resorbed cadmium accumulates in the renal cortex, where it has
a half time of over 10 years. Several studies have indicated that cadmium kinetics
may be dose-dependent, and possibly also dependent on exposure path (30). Much
of the cadmium taken up by the mucous cells in the digestive tract (long-term,
low-level exposure) is bound directly to MT in the cells. Some of this cadmium
can be excreted in feces when these cells are sloughed off, whereas the absorbed
Cd-MT complex is transported in the blood, mostly to the kidneys.
The half time for cadmium in blood has two phases – a short phase of 75 to
128 days and a longer phase of 7.4 to 16 years – that reflect the body burden (24).
Cadmium is excreted slowly in urine, with a half time of about 10 to 15 years
(equivalent to a daily excretion of about 0.01 percent of the body burden).
Biological markers for exposure and dose
Routine exposure control is traditionally based on determination of cadmium
in blood and urine. The cadmium content in blood reflects primarily current
exposure (but can also be used as a measure of body burden a few years after
occupational exposure has stopped; see above), whereas the cadmium content in
urine is related primarily to the body burden. Cumulative blood cadmium (blood
cadmium content multiplied by years of exposure, expressed in nmol/l x years)
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can also be used as a measure of body burden (23, 25). However, cadmium in
urine rises if there is kidney damage – no matter what the cause (30). Refinements
in analysis methods over recent years have made it possible to lower the detection
limits. At present Inductively Coupled Plasma Mass Spectrometry (ICP-MS) has
largely replaced atomic absorption (AAS) for determination of cadmium in blood
and urine. To compensate for the inconsistent water content in urine, cadmium in
urine is usually given in relation to the amount of excreted creatinine.
In vivo methods – neutron activation (NA) and x-ray fluorescence (XRF) – have
been developed to determine cadmium in kidneys and liver. These methods allow
direct determination of cadmium in these organs, but are still far too complicated
and uncertain to provide a feasible alternative to cadmium in blood or urine as a
measure of dose (9, 10, 30).
Biological markers for kidney damage
Tubular damage
There are several sensitive methods for assessing the function of renal tubuli (13).
Low-molecular proteins such as ß2-microglobulin, retinol-binding protein (RBP)
and Human Complex-forming glycoprotein (Protein HC = α1-microglobulin), as
well as tubular intracellular enzymes (e.g. N-acetyl-ß-D-glucosaminidase, NAG),
have all been used to detect early damage to renal tubuli. It is important to bear in
mind, however, that increased excretion of such proteins or enzymes is not
necessarily caused by cadmium or other heavy metals. Urinary excretion of ß2-
microglobulin may increase with fever or urinary infections, for example. A major
disadvantage of ß2-microgobulin is that the protein is unstable at low pH (<5.6) in
urine. Other alternatives (such as α1-microglobulin) may therefore be preferable
for epidemiological studies of cadmium exposure and early kidney damage.
Glomerular damage
The function of the renal glomeruli, GFR (Glomerular Filtration Rate), is usually
determined with methods that measure how fast an injected foreign substance –
often a very small amount of radioactively labeled CrEDTA or the contrast
medium Iohexol – is eliminated from the blood via the kidneys. A commonly
used method for rough determination of GFR is to measure creatinine in serum;
however, this usually does not rise until the GFR has dropped to about half the
normal value, i.e. with considerably reduced renal function. S-Cystatin C has
recently come into use as a marker for glomerular damage (59). Increased
glomerular permeability results in a rise in the content of large proteins (albumin)
and/or blood cells in the urine. Analysis for these is often used in occupational
medicine to detect early glomerular damage (69).
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Toxic effects
Acute effects
Inhalation of high concentrations of cadmium (1 mg/m3 or higher) can be lethal
(45). Acute pulmonary effects and deaths are rare, but still occur occasionally (4,
53).
Kidney damage
Tubular damage
It is well documented that long-term exposure to cadmium causes kidney damage
(30). The damage is usually to the renal tubuli, and is characterized by increased
excretion of low-molecular proteins (see above under Biological markers for
kidney damage). Most of the kidney damage is probably localized in the proximal
tubuli. It has sometimes been argued that the tubular damage is reversible, but the
evidence is weak (19, 64). On the other hand, there is convincing evidence that the
tubular damage caused by cadmium is not reversible (30, 50).
In a summary of the situation in 1992, WHO stated that excretion in urine of
10 nmol Cd/mmol creatinine (corresponding to about 200 mg Cd/kg renal cortex)
was a “critical limit” below which kidney damage could not occur (70). However,
WHO also estimated that about 10 percent of individuals with this much cadmium
in their kidneys would suffer tubular damage. Several reports published since then
have indicated that the “critical concentration” of cadmium in urine and kidney
tissue is probably much lower. In other words, early kidney damage and/or
skeletal effects probably occur at levels below the critical limit published by
WHO.
In a study of occupationally exposed workers (76 men) in the United States it
was found that a U-Cd content of 6.8 nmol/mmol creatinine was associated with
a 10% prevalence of tubular proteinuria (39), and a study from Singapore reported
a significantly elevated age-standardized prevalence of two sensitive markers
for tubular damage (U-α1-microglobulin and U-NAG) at U-Cd levels exceeding
5 nmol/mmol creatinine in a group of workers (45 men and 52 women) in a
nickel-cadmium battery factory (11).
In a frequently cited Belgian study (Cadmibel) of cadmium’s effects in the
general population (n = 2327), indications of cadmium-induced kidney damage
were found in about 10% of subjects with urine concentrations of about 2 to 3
nmol Cd/mmol creatinine (adjusted for other significant variables) (8). It should
be noted that this figure includes a “background prevalence” of 5%, since
“elevated values” were defined as those lying above the 95th percentile in a
reference population. This method of calculating, however, is usual in studies of
kidney damage caused by cadmium. The authors observed that, despite the fact
that the body burden of cadmium increases with age, the effects of cadmium on
the studied markers for kidney damage were independent of age and gender.
Diabetics were reported to be particularly sensitive. A more recent Belgian study
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(57) confirms these earlier results (8). It was found that people living in cadmium-
contaminated areas had elevated excretion of several markers for tubular damage.
A Japanese study of the population in a cadmium-contaminated area (1403 men
and 1716 women; 478 men and 696 women in a reference population) showed
dose-response relationships between urine cadmium, age and ß2-microglobulinuria
(15). The prevalence of tubular proteinuria was 14.3 for men and 18.7 for women
in the exposed group, with an odds ratio of 4.11 (no confidence interval was
given) for tubular proteinuria among the exposed subjects (average U-Cd = 5
nmol/mmol creatinine) compared with unexposed subjects (average U-Cd = 2
nmol/mmol creatinine). It should be mentioned that the limit for tubular damage
was set at 1000 µg ß2-microglobulin/g creatinine ( = 113 µg/mmol creatinine),
which is quite a bit higher than limits usually applied outside Japan (e.g. 34
µg/mmol creatinine). It was calculated that a 10% prevalence of tubular protein-
uria corresponded to a U-Cd excretion of 1.6 – 4.6 nmol/mmol creatinine, which
is similar to the results from Belgium.
A recently published Swedish study including both occupationally exposed
workers and an environmentally exposed population showed a clear dose-response
relationship between cadmium in urine and damage to renal tubuli (see also Table
1), with a prevalence of 10% at a U-Cd content of 1.0 nmol Cd/mmol creatinine,
adjusted for the average age of the subjects (53 years) (33).
Yet another newly published study (151 women, 159 men) reports a dose-
effect relationship between markers for kidney damage (NAG, alanine-amino
peptidase (AAP)) and cadmium in urine at very low concentrations: < 0.25 to ≥ 1
nmol/mmol creatinine; at ≥1 the markers were significantly higher than at < 0.25
(43). However, it is difficult to interpret these findings in terms of damage.
Although the subjects of occupational exposure studies are usually young or
middle-aged men, there are also high-risk groups in the general population. For
example, women are more likely than men to suffer from iron deficiency, a
condition facilitating the absorption of cadmium. Old people are another high-risk
group. It is therefore not surprising that tubular damage was observed in the
general population at lower cadmium levels than in the occupationally exposed
subjects. Kidney function normally declines with advancing age, most notably
GFR but also to some extent tubular function. It should be mentioned that most of
the earlier studies do not take the effect of age into the calculations; however, it is
judged to be rather small (30).
Correlations between exposure (air), dose (blood, urine) and prevalence of
damage to renal tubuli have thus been demonstrated in several studies, a few of
which are presented in Table 1. Cadmium oxide is the compound most common in
occupational exposures (in Sweden), although a few studies have addressed other
compounds (e.g. sulfide) and environments (e.g. zinc smelters). The studies
shown in Tables 1a and 1b are of exposure to cadmium oxide (CdO).
                                    
1
 It should be mentioned that prevalence odds ratios tend to overestimate the actual risk – and the
higher the prevalence the higher the overestimate.
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Table 1a. Correlations between exposure to CdO and prevalence of damage to renal
tubuli. Marker for tubular damage: ß2-microglobulin. Cutoff level: 34 µg/mmol
creatinine, corresponding to a background prevalence of 2.5%.
Exposure/dose/exposure measure
Interval (arithmetic mean)
Number of
persons
Prevalence
(%)
Ref.
Cumulative air concentration
µg/m3 x years
25
<359
359-<1710
1710-<4578
4578-<9458
9458-<15,000
≥15,000
264
76
43
31
16
10
1.1
9.2
23
32
31
50
Cumulative blood concentration
nmol/l x months
25
<5,000
5,000-<10,000
10,000-<15,000
15,000-<30,000
30,000-<60,000
≥60,000
221
87
38
48
27
16
1.4
4.6
16
23
30
50
Cadmium in urine
nmol/mmol creatinine
28
<1
1-<3
3-<5
5-<10
≥10
(0.45)
(1.67)
(3.98)
(7.04)
(15.07)
248
165
63
57
28
0.8
2.4
14
28
46
Table 1b. Correlations between exposure to CdO and prevalence of damage to renal
tubuli. Marker for tubular damage: protein HC (α1-microglobulin). Cutoff levels: 0.6
mg/mmol creatinine for women, 0.8 mg/mmol creatinine for men, corresponding to a
background prevalence of 5%. (from Reference 33)
Measure of exposure
Interval
Number of persons Prevalence
(%)
(arithmetic mean) Total Occupationally
exposed
Total Occupationally
exposed
Cadmium in urine
nmol/mmol creatinine
<0.3
0.3-<0.5
0.5-<1
1-<2
2-<3
3-<5
≥5
(0.21)
(0.38)
(0.69)
(1.4)
(2.5)
(3.8)
(6.8)
265
273
298
108
24
21
12
  13
  30
  66
  55
  23
  20
  12
4.9
14
23
30
33
33
50
  7.7
  13
  12
  18
  30
  35
  50
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Other effects on kidneys
As early as 1950 it was noticed that cadmium-exposed workers could have low
GFR in addition to proteinuria (14). This was subsequently confirmed in several
studies of occupationally exposed workers (30). Järup et al. (29) examined
cadmium-exposed solderers, and found correlations between cadmium dose,
degree of tubular damage (measured as ß2-microglobulin clearance) and declining
age-adjusted GFR. At a blood cadmium level of 100 nmol/l GFR had dropped to
80% of the reference level, and an elevated prevalence of reduced GFR was seen
at levels as low as 50 to 75 nmol/l. Other studies have shown that glomerular
damage can be independent of tubular damage (6).
An elevated incidence of kidney stones among workers occupationally
exposed to cadmium has been found in several studies (30). The kidney stones
were usually associated with tubular proteinuria, and may possibly be related to
increased excretion of calcium in urine due to the tubular damage. A dose-
response relationship between cumulative exposure to airborne cadmium and
age-adjusted cumulative incidence of kidney stones has been reported (27). The
median cadmium content in the urine of worker with kidney stones was 3.7 (95%
Confidence Interval (CI): 2.4 – 6.4) nmol/mmol creatinine.
A relation between cadmium exposure and kidney failure has also been reported
in a recent ecological study (17). The study reviewed records of patients treated
for chronic uremia, and found a nearly doubled risk for persons living less than
2 km from the source of exposure (SRR = 1.9; 95% CI: 1.3 – 2.5) and for those
occupationally exposed (SRR = 2.3; 95% CI 0.6 – 6.0) when these groups were
compared to unexposed subjects in the same district (Kalmar county).
Skeletal damage (effects)
Long-term exposure to cadmium can cause bone disease, which was first reported
from Japan, where itai-itai (it hurts-it hurts) (a combination of osteomalacia and
osteoporosis) was first diagnosed in the 1950s. The source of exposure was
cadmium-contaminated water that was being used to irrigate the local rice fields.
The cadmium content in the bones of itai-itai patients was found to be several
times as high as that in unexposed persons. There are also a few reports of similar
skeletal effects from sources outside Japan (30).
Reduced bone density after exposure to cadmium is described in a few animal
studies. An American study of beagles showed that bone loss could appear at
fairly low blood cadmium levels (27 - 71 nmol/l) (7). The results indicated that
cadmium affects the bones directly.
Some data published in the past few years indicate that even relatively low
exposure to cadmium can cause skeletal damage in the form of reduced bone
density and fractures. A Belgian study of persons living in cadmium-contaminated
areas showed a relationship between elevated excretion of cadmium in urine and
reduced bone density/fractures (58). A doubling of the urine cadmium level was
associated with a significant elevation in relative risk for fractures (RR = 1.73;
95% CI: 1.16 –2.57). In a Swedish study of occupationally exposed brazers (hard
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solder) it was found that reduced bone density was positively correlated to age
and to blood cadmium (which in this group of workers was found to be a relevant
measure of the body burden) (31). Brazers with tubular damage had lower bone
density than the others. These results were later confirmed in a study of 1064
persons occupationally or environmentally exposed to cadmium (2). This study
reports both dose-effect and dose-response relationships between urine cadmium
and reduced bone density (osteoporosis), with odds ratios of 2.2 (95% CI: 1.0 –
4.8) for men 60 or older in the dose group 0.5 – 3 nmol Cd/mmol creatinine, and
5.3 (95% CI: 2.0 – 14) for those in the highest dose category (3 nmol Cd/mmol
creatinine or higher) compared with the lowest group (< 0.5 nmol Cd/mmol
creatinine). For women aged 60 or older the odds ratio was 1.8 (95% CI: 0.65 –
5.3) in the dose group 0.5 – 3 nmol Cd/mmol creatinine; there were no women
in the high-dose group.
These reports indicate that bone damage associated with cadmium can occur at
much lower cadmium concentrations than was earlier believed.
Neurological effects
Animal studies have shown that cadmium can be neurotoxic, but few studies have
found neural damage in human subjects. Slightly reduced functional ability on
psychological tests has been reported in occupationally exposed subjects (45). In
one study, effects on the central nervous system (e.g. longer reaction times) were
seen in neuropsychological tests given to a group of workers with various degrees
of cadmium exposure (average value in urine = 12.6 nmol Cd /mmol creatinine;
range 0.4 – 38.4) (66). This group also had a higher (dose-dependent) incidence
of peripheral neuropathy than a control group. In a study of retired workers, the
cadmium-exposed group had a much higher risk of polyneuropathy than a control
group (odds ratio = 9.92; 95% CI: 1.60 – 61.6) (65). The prevalence of poly-
neuropathy was related to the body burden of cadmium.
Effects on the heart and circulatory system
Data from animal experiments have suggested that cadmium might be a risk factor
for cardiovascular disease, but this has not been confirmed in studies of humans
(30, 35, 70). Data from the previously mentioned Cadmibel study gave no support
to the hypothesis that cadmium exposure would lead to a heightened prevalence of
hypertonia or cardiovascular disease (8). On the other hand, a Japanese study
showed an elevated risk of mortality due to cardiovascular disease in cadmium-
exposed subjects with indications of damage to renal tubuli (65 men and 113
women) when they were compared to persons without kidney damage (1014 men
and 1216 women) (41). In a follow-up study of a Swedish cohort of nickel-
cadmium battery workers, no increase in risk of mortality due to cardiovascular
disease was found when they were compared with a regional (Kalmar county)
reference population (32).
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Mortality
Studies of persons from cadmium-contaminated areas in Japan who have
cadmium-induced kidney damage (ß2-microglobulin ≥ 1000 µg/g creatinine)
have shown a clear connection between degree of kidney damage and elevation
in mortality (3, 40). Similar findings were made earlier in other cadmium-
contaminated areas in Japan (21, 22). Although it is not clear from the Japanese
studies, there is reason to believe that much of the increased mortality can be
ascribed to chronic kidney failure. In this context it can be mentioned that the
prevalence of active uremia care in Japan is two to four times as high as it is in
Europe (62).
Mutagenicity
Mutagenicity tests with bacteria have generally been negative, and studies of
chromosome aberrations in persons occupationally exposed to cadmium have
been inconclusive (45). It has been proposed that cadmium might inhibit DNA
repair and thus have a synergistic effect with some mutagens and carcinogens
(51). One review article concludes that cadmium is probably not mutagenic and
that its possible carcinogenic qualities seem to be due to indirect, thus far
unknown, mechanisms (68).
Carcinogenicity
Human data
Lung cancer
In its most recent carcinogenicity assessment of cadmium, the IARC stated that
there was “sufficient evidence” for classifying cadmium as a human carcinogen
(Group 1) (20). However, the IARC pointed out that the assessment was based on
only a few studies of occupationally exposed persons and that there were often
shortcomings in the exposure data. As a rule, possible confounding factors such as
smoking and simultaneous exposure to other substances such as nickel and arsenic
could not be included. The IARC assessment was based largely on studies from
the U.S. with few cases of lung cancer (63). Statistically significant dose-response
relationships were shown with several different regression models (60). From this
analysis it was estimated that exposure to cadmium (smoke) at 100 µg/m3 should
give rise to about 50 - 111 lung cancer cases in 1000 workers exposed to cadmium
for 45 years. The American studies have been criticized, mostly on the basis of
inadequate control for confounding factors – especially arsenic (30). Sorahan and
Lancashire re-analyzed the American cohort, including in their analysis data on
arsenic exposure (56). They found that there was still a dose-response relationship
between cumulative cadmium exposure and lung cancer, but only in combination
with arsenic exposure. The increase in lung cancer risk may also be due to the
arsenic exposure alone. No risk increase for lung cancer was found in an English
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study; there was a negative correlation between cumulative cadmium exposure
and lung cancer risk (55). These findings are supported by a Swedish study in
which, although the most recent follow-up (to 1992) of a cohort of nickel-
cadmium battery workers revealed a statistically significant increase in the risk of
death due to lung cancer (SMR = 176; 95% CI: 101 – 287), and a nearly signifi-
cant risk increase for lung cancer incidence (SMR = 173; 95% CI 97 – 285), there
was a negative dose-response relationship between cumulative cadmium exposure
and lung cancer risk (32). The same results were obtained when smoking habits
were included in the analysis. It should be observed, however, that a negative
trend based on SMR values can be false due to problems in comparing SMRs for
sub-groups with different age structures (38). Further, a negative trend may be due
to the “healthy worker” effect, which is often more pronounced in sub-groups
with many years of employment (46).
Prostate cancer
It has long been suspected that cadmium might cause prostate cancer (48), but this
has not been confirmed in recent studies. Studies that show somewhat higher risks
have been published, as have studies that are negative (30). This inconsistency has
also been commented by the IARC (20).
Renal cancer
Some early data indicated a connection between cadmium exposure and renal
cancer (34). Later studies have been unable to clearly confirm this, though a large
multi-center study showed a (nearly) significant increase in relative risk of renal
cancer (RR = 2.0; 95% CI 1.0 – 3.9), but with a negative dose-response
relationship arguing against a causal relationship (37). A population-based multi-
center study with 935 cases of renal cancer found an elevated risk associated with
occupational exposure to cadmium (OR = 1.4, 95% CI: 1.1 – 1.8 for men; OR =
2.5, 95% CI: 1.2 – 5.3 for women) (47).
Other forms of cancer
It has been suggested that cadmium increases the risk of testicular cancer (49),
bladder cancer (54) and pancreatic cancer (52), but the evidence is weak.
Animal data
It has been shown in several laboratory studies that cadmium can cause tumors in
animals (30). The IARC, in its most recent assessment, concluded that there is
“sufficient evidence” that cadmium is carcinogenic, but also pointed out that the
evidence that cadmium is carcinogenic when given orally to experimental animals
is limited (20). The carcinogenic effects on laboratory animals have usually been
observed after inhalation or injection of cadmium compounds.
The mechanisms behind cadmium’s ability to induce prostate cancer have been
discussed (67). The authors observed in summary that, in long-term studies with
rats, the cadmium-induced tumors occur mainly in the ventral prostata regardless
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of whether the exposure was oral, parenteral or by direct injection. It should be
mentioned that cadmium treatment can induce several different types of tumors in
prostata, including invasive adenocarcinoma. According to the authors these
results with rats support the hypothesis that cadmium may have a role in causing
prostate cancer in humans.
International classifications
The IARC has classified cadmium as a human carcinogen (Group 1), meaning that
there is adequate evidence of carcinogenicity from studies of both humans and
experimental animals. However, recent epidemiological studies (reviewed above)
do not support this assessment – notwithstanding the data indicating that cadmium
can be carcinogenic to laboratory animals. The evidence that cadmium is a human
carcinogen is rather weak, especially for oral exposure. A classification of
cadmium as “probably carcinogenic to humans” (IARC Group 2A) would
probably be more reasonable (30). This conclusion is in accord with the EU
classification of some cadmium compounds (Carcinogen Category 2 with
inhalation; Annex 1 to the directive 67/548/EEC).
Effects on reproduction
Teratogenic effects have been observed in experimental animals exposed to
cadmium (usually after injection of high doses), whereas the few studies made
of humans have been inconclusive (16, 30, 45). A study of 149 industrial workers
exposed to lead at work and cadmium via smoking indicated that moderate blood
levels of lead (< 400 µg/l = 2 µmol/l) and cadmium (< 10 µg/l = 90 nmol/l) can
lower semen quality (61).
In summary, there is no conclusive evidence that cadmium has effects on
reproduction, although the question remains open (16, 30).
Dose-effect / dose-response relationships
Exposure to cadmium concentrations exceeding 1 mg Cd/m3 can result in acute,
severe effects on the lungs (edema, pneumonitis) (45).
Relationships between cadmium dose and effects on kidneys are illustrated
in Table 2. NAG and AAP in urine were measured in one study and were
significantly higher at ≥ 1 than at < 0.25 nmol Cd/mmol creatinine (43).
Present Swedish regulations for biological control of occupational exposure to
cadmium, with reference to the threshold values recommended by WHO, define
persons “who do not run a substantial risk of kidney damage (i.e. Cd in blood <
200 nmol/l and Cd in urine < 10 nmol/mmol creatinine)” (National Swedish
Board of Occupational Safety and Health, AFS 2000:7). Table 1 shows that there
are clear relationships between exposure to airborne cadmium, absorbed dose
(blood, urine) and tubular proteinuria, and that damage to renal tubuli can develop
at cadmium concentrations much lower than those previously considered safe.
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 Table 2. Dose-effect relationships between cadmium dose (measured in urine
and/or blood) and effects on kidneys.
Dose measure Effect Ref.
U-Cd (nmol/mmol B-Cd
creatinine) (nmol/l)
<0.25 – ≥1 Increasing NAG and AAP with
increasing U-Cd, significantly
higher at U-Cd ≥ 1 nmol/mmol than
at < 0.25.
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1 - 3 Damage to renal tubuli (proteinuria) 8, 33
50 - 75 Glomerular damage (reduced GFR) 29
> 4 > 60 Kidney stones 27
Studies of Swedish battery workers show an elevated risk for damage to
renal tubuli at about 3 nmol Cd/mmol creatinine. U-Cd above 3 nmol/mmol
creatinine was associated with a 5 to 15 percent prevalence of ß2-microglobulin-
uria (depending on age) (26). The correlation between cadmium in urine (at levels
above 3 nmol/mmol creatinine) and cumulative exposure to airborne cadmium is
described by the following equation (26, 28):
Ln(U-Cd, nmol/mmol creatinine) = -1.7 + 0.38 x ln(cumulative air Cd, µg/m3 x years)
Thus a U-Cd value of 3 nmol/mmol creatinine is approximately equal to 1500
µg/m3 x years of exposure, or in other words about 30 years of exposure to air
concentrations corresponding to the exposure limits now in force in Sweden (50
µg/m3 total dust). An air concentration calculated from U-Cd ≤ 3 nmol mmol
creatinine would be altogether too uncertain. A 10% prevalence of proteinuria was
found in workers aged 60 or more at levels as low as 1.5 nmol/mmol creatinine,
whereas in younger workers this prevalence was seen at 5 nmol/mmol. The higher
prevalence in older workers may be due to degenerative changes in the renal
tubuli, since aging is associated with increasing sensitivity to cadmium and
consequent acceleration of cadmium-induced tubular damage.
Studies published so far indicate that damage to renal glomeruli seldom occurs
below the levels at which tubular damage occurs, but the Japanese studies have
shown dose-response relationships between cadmium dose and mortality (42).
Both animal studies and human data indicate that bone damage (osteoporosis)
can be a critical effect of cadmium exposure, but it is still too early to draw
definite conclusions regarding the relevance of these findings to human health.
It should, however, be emphasized that osteoporosis is a major public health
problem and that further studies are planned to clarify the role of cadmium in
development of osteoporosis. When the results of these studies are known, it
may be necessary to re-evaluate the critical effect of cadmium exposure.
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Conclusions
The critical effect of exposure to cadmium is probably the damage to renal tubuli,
but data from two large European studies indicate that bone damage can occur at
equally low levels. New data indicate an elevated risk of tubular damage at urine
levels around 1 nmol Cd/mmol creatinine. The studies are based mainly on
environmental exposures and air concentrations are not given. Calculation of air
concentration based on such a low U-Cd level would be altogether too uncertain
to provide a meaningful value.
Cadmium has been judged by the IARC to be carcinogenic to humans, but
recently published data do not support this assessment.
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Consensus Report for Chlorobenzene
April 2, 2003
This Consensus Report is based on a criteria document compiled jointly by the
National Institute of Occupational Safety and Health (NIOSH) in the USA and the
Swedish Criteria Group (5), and on a document from DFG (1). The Criteria Group
published a previous Consensus Report on chlorobenzene in 1993 (8).
Physical and chemical data. Uses
CAS No. 108-90-7
Synonyms: monochlorobenzene, benzene chloride,
phenyl chloride
Formula: C6H5Cl
Structure:
Molecular weight: 112.56
Melting point: - 45 °C
Density: 1.11 g/ml (20 °C)
Boiling point: 131 - 132 °C
Vapor pressure: 1.58 kPa (25 °C)
Flash point: 28 °C
Saturation concentration: 15,600 ppm
Distribution coefficient: log Pow: 2.84
   (n-octanol/water)
Conversion factors (20 °C): 1 ppm = 4.60 mg/m3
1 mg/m3 = 0.217 ppm
At room temperature chlorobenzene is a clear liquid with an odor similar to that of
benzene. The odor threshold is reported to be between 1 and 3 mg/m3 (0.21 -- 0.68
ppm). Chlorobenzene is insoluble in water but dissolves readily in oils and mixes
with alcohol, chloroform, benzene and other organic solvents. Chlorobenzene is
used industrially in chemical syntheses and as a solvent and de-greaser.
Cl
49
Uptake, biotransformation, excretion
Chlorobenzene can be absorbed via the lungs and digestive tract. No data on
skin uptake were found (5). When radioactively labeled chlorobenzene was
given to rats, the radioactivity was rapidly distributed to body organs: the highest
concentration was in fatty tissue, followed by kidney, liver and brain (5).
Chlorobenzene is metabolized primarily by the P-450 system (CYP2E1 and
CYP3A) in various organs (mostly the liver) and excreted in urine. Electrophilic
epoxides are formed as intermediates and are conjugated to water-soluble
metabolites by glutathione transferases. Hydroxylated metabolites such as
methachlorophenol are also formed: these are further metabolized to water-soluble
compounds, usually via glutathione conjugation. The toxic effects of chloro-
benzene are attributed to the formation of epoxides and their ability to bind to
macromolecules (3, 5). It has been found that chlorobenzene is metabolized
differently by different species and that CYP2E1 plays the largest role in its
biotransformation (15). Human liver microsomes have higher transformation
activity than liver microsomes from rodents (rats and mice), and are thus more
efficient metabolizers of chlorobenzene. The human microsomes produced a
smaller amount of covalently bound metabolites, however (15). This study also
revealed large individual differences in the amount of CYP2E1 in human liver
microsomes, with some containing up to five times as much as others. Epoxides
are inactivated by the enzyme epoxide hydrolase, and its activity has been shown
to be greater in human liver than in rodent liver (4). This may mean that humans
are less sensitive to epoxide-mediated toxicity, but it is possible that the
simultaneously formed catechols also have toxic properties (6).
The metabolites 4-chlorocatechol, 2-chlorophenol, 3-chlorophenol, 4-chloro-
phenol and 4-chlorophenylmercapturic acid have been identified in the urine of
humans exposed to chlorobenzene (12). The main metabolite formed in people
exposed on the job or in inhalation experiments has been found to be 4-chloro-
catechol (75% of the metabolites in urine) (10). In animal studies, 60% of the
chlorobenzene dose has been identified in urine as 4-chlorophenylmercapturic
acid, regardless of exposure path (1, 11). In an inhalation study, volunteers were
exposed to 10 ppm (46 mg/m3) chlorobenzene 8 hours/day for 5 days: a two-
phase elimination of chlorobenzene in blood was reported, with a half time of
53 minutes during the first hour of exposure and 150 minutes thereafter. The half
times for metabolites in blood were 6.4 hours for 4-chlorocatechol and 12.4 to
16.5 hours for the chlorophenols (13% of the metabolites in urine). Eighty percent
of the total amount of metabolites was excreted in urine within 16 hours. No
accumulation of chlorobenzene or its metabolites was registered during the
week of exposure (10). No effects on health were mentioned in the article (10).
4-chlorocatechol in urine has been proposed as a biological exposure indicator for
chlorobenzene (1, 5).
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Toxic effects
Human data
There are a few studies (older case reports of acute poisoning) that describe
symptoms in exposed persons. In acute poisoning in cases of attempted suicide the
toxic picture is dominated by severe effects on the central nervous system (1, 5).
In a Japanese study, 5 volunteers (the authors of the article) were exposed to 275
mg/m3 chlorobenzene for 7 hours (3 hours in the morning and 4 in the afternoon).
The exposure elicited subjective symptoms such as drowsiness (in all five),
headache ("75%") and throbbing pain in the eyes ("50%"). Some deterioration
in the results of a neuropsychological test (flicker fusion) was noted after the first
3 hours of exposure, but was no longer measurable after the afternoon exposure
session (17).
Animal data
The acute toxicity of chlorobenzene is relatively low. The LC50 for various
laboratory animals has been found to be above 8000 mg/m3 with at least 6 hours
of exposure, and the lowest LD50 values are above 1000 mg/kg. Chlorobenzene in
high doses has effects on the nervous system: tremor, muscular spasms, breathing
difficulty, drowsiness, ataxia and paralysis (5).
Repeated exposure to chlorobenzene, whether in oral doses or by inhalation, has
been shown to damage liver and kidneys. Typical indications of liver damage are
increase of ALAT and ASAT and effects on liver weights. Increased liver weights
are reported after single doses above 200 mg/kg. In an 11-week inhalation study
with rats, the LOEL (Lowest Observed Effect Level) for increased liver weight
(hypertrophy) was 230 mg/m3 (the lowest exposure level) (14). In a 13-week
study in which rats were given chlorobenzene orally, the LOEL for this effect
was 125 mg/kg and the NOEL (No Observed Effect Level) was 60 mg/kg (9).
In a 13-week study with mice (oral administration), the LOEL for dilation of
renal tubules and interstitial nephritis (kidney inflammation) was 250 mg/kg/day
and the NOEL 125 mg/kg/day (9). In an 11-week inhalation study with rats, the
LOEL for this effect was 690 mg/m3 and the NOEL 230 mg/m3 (14).
Effects on other organs have also been reported. Mice exposed to 250 mg/kg
chlorobenzene daily for 13 weeks had reduced numbers of lymphoid and myeloid
cells in the spleen and necroses in the thymus (NOEL 125 mg/kg/day). In the
same study, bone marrow depression was seen in rats after 13 weeks of exposure
to 500 mg/kg/day chlorobenzene (NOEL 250 mg/kg/day) (9). Elevated lung
weights were registered in rabbits that had been exposed to 345 mg/m3 chloro-
benzene for 24 weeks (5). In an inhalation study, mice (5 males and 5 females per
group) were exposed to 100 mg/m3 chlorobenzene 7 days/week for 3 months: the
exposure resulted in leucopenia and effects on bone marrow (18). Exposure
conditions are poorly described, however, and the concentration in the exposure
chamber may have been uneven and dose estimates consequently either too high
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or too low. In a more recent study with oral exposures, the reported NOEL for
similar effects is 250 mg/kg for rats and 125 mg/kg for mice (9).
Chlorobenzene is moderately irritating to skin and eyes, but showed no
sensitizing effect on guinea pigs in the Guinea Pig Maximization Test (1).
Genotoxicity, carcinogenicity
It is suspected that chlorobenzene may be a low-potency genotoxic substance,
since some studies indicate that it is genotoxic although most of them do not (1,
5). The question of chlorobenzene's genotoxicity is discussed in greater detail
in the Criteria Document (5). Results have been negative in most genotoxicity
tests with bacteria (1, 5). However, chlorobenzene was mutagenic in a mouse
lymphoma test, both with and without metabolic activation. No DNA-damaging
effects have been detected either in bacterial tests or in an "unscheduled DNA
synthesis" test with mammalian cells. Chlorobenzene showed no clastogenic
activity in Chinese hamster ovary (CHO) cells, but there was an increase in the
number of sister chromatid exchanges (SCE) in CHO cells in the absence of
metabolizing systems. Most in vivo studies have produced negative results.
Negative results were obtained in the recessive lethal test with Drosophila
melanogaster. Tests for chromosome aberrations and micronuclei have also been
negative. Positive results were obtained in one in vivo test for micronuclei, but the
validity of this result has been questioned (1). Weak covalent binding to DNA has
been shown both in vivo and in vitro. Binding to RNA and protein has also been
demonstrated in vivo after an intraperitoneal injection of chlorobenzene (3). An
adduct, N7-phenylguanine, has been identified in the urine of rats exposed to
chlorobenzene (11).
Chlorobenzene was tested for carcinogenic activity in a cancer study (16).
Groups of 50 rats and mice were given chlorobenzene orally for 103 weeks. The
only significant effect was an increased occurrence of benign neoplastic nodules
in the livers of the male rats exposed to the highest dose (120 mg/kg) (untreated
controls: 4/50; vehicle (corn oil) only: 2/50; 60 mg/kg: 2/50; 120 mg/kg: 8/49).
One female rat in the high-dose group had tubular adenocarcinoma in kidneys.
One male in the low-dose group and one in the high-dose group had transitional-
cell papillomas in the urinary bladder. This was given specific mention since these
tumor forms are extremely rare in rats (0/789 and 0/788 in historic controls).
Despite this result, the EPA (2) has stated that for chlorobenzene there is
"inadequate evidence of carcinogenicity " (Group D).
Effects on reproduction
An exposure of 2714 mg/m3 6 hours/day on days 6 - 15 of gestation induced
skeletal anomalies in fetuses of rats and rabbits. However, since the exposure
was also toxic to the mothers, the authors did not regard this as an indication of
teratogenic effect (7). In a two-generation study animals were exposed to up to
2070 mg/m3 chlorobenzene 6 hours/day, 7 days/week for 11 weeks. The F1
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generation had elevated liver weights (690 mg/m3 and higher), but no fetotoxic
effects or effects on fertility were observed (14). However, there were degen-
erative changes in germinal cell epithelium in testes (LOEL 690 mg/m3; NOEL
230 mg/m3).
Dose-response / dose-effect relationships
There are no data on which to base a dose-response or dose-effect relationship for
humans. The five subjects in an exposure-chamber study (275 mg/m3) reported
subjective symptoms such as drowsiness, headache and a throbbing ache in the
eyes and had poorer results on a neuropsychological test. As for long-term animal
studies, the LOEL and NOEL values and the observed effects are given in Table
1. The LOEL values for effects on the liver are about the same for inhalation and
oral administration. There is an inhalation study describing effects on bone
marrow at an exposure level of 100 mg/m3, but the exposure conditions leave
room for error and these results are contradicted by a 2-year study in which no
similar effects were observed.
Table 1. Effects on laboratory animals exposed to chlorobenzene.
Exposure Species Effect Ref.
Inhalation, 11 weeks
690 mg/m3
230 mg/m3
Rat Degeneration of germinal epithelium in testes
LOEL
NOEL
14
Inhalation, 11 weeks
690 mg/m3
230 mg/m3
Rat Interstitial nephritis
LOEL
NOEL
14
Inhalation, 24 weeks
345 mg/m3
Rabbit Increased lung weight 5
Inhalation, 11 weeks
230 mg/m3
Rat Increased liver weight
LOEL
14
Gavage, 5 days/week,
13 weeks
500 mg/kg/day
250 mg/kg/day
Rat Effects on bone marrow
LOEL
NOEL
9
Gavage, 5 days/week,
13 weeks
250 mg/kg/day
125 mg/kg/day
Mouse Interstitial nephritis
LOEL
NOEL
9
Gavage, 5 days/week,
13 weeks
250 mg/kg/day
125 mg/kg/day
Mouse Lymphoid and myeloid cell depletion in spleen
LOEL
NOEL
9
Gavage, 5 days/week,
13 weeks
125 mg/kg/day
60 mg/kg/day
Rat Higher liver weights
LOEL
NOEL
9
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Conclusions
There are no data that can serve as a basis for establishing a critical effect of
occupational exposure to chlorobenzene. The subjects in an exposure chamber
study reported CNS effects (subjective symptoms) at a concentration of 275
mg/m3. In animal experiments, liver enlargement has been observed (LOEL 230
mg/m3 for 11 weeks), and at high exposure levels effects on kidneys and testes.
Chlorobenzene can also affect bone marrow, but it is not clear whether this occurs
at the LOEL for effects on the liver. Judging from animal experiments in which
chlorobenzene was given by gavage, effects on bone marrow occur at higher
exposure levels.
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Consensus Report for Lithium and
Lithium Compounds
June 4, 2003
This report is based on a criteria document compiled by the Nordic Expert Group
(16).
Chemical and physical data
Substance
(Synonym)
Chemical formula Molecular
weight
    CAS no.
Lithium Li     6.94   7439-93-2
Lithium hydride LiH     7.95   7580-67-8
Lithium aluminum hydride
   (Li-tetrahydroaluminate)
LiAlH4   37.95 16853-85-3
Lithium borohydride
   (Li-tetrahydroborate)
LiBH4   21.78 16949-15-8
Lithium oxide Li2O   29.88 12057-24-8
Lithium hydroxide LiOH   23.95   1310-65-2
Lithium hydroxide monohydrate LiOH.H2O   41.96   1310-66-3
Lithium nitride Li3N   34.83 26134-62-3
Lithium amide LiNH2   22.95   7782-89-0
Lithium nitrate LiNO3   68.94   7790-69-4
Lithium carbonate Li2CO3   73.89     554-13-2
Lithium sulfate Li2SO4 109.94 10377-48-7
Lithium fluoride LiF   25.94   7789-24-4
Lithium chloride LiCl   42.39   7447-41-8
Lithium bromide LiBr   86.84   7550-35-8
Lithium acetate LiCH3COO   65.99     546-89-4
Lithium acetate, dihydrate LiCH3COO·2 H2O 102.01   6108-17-4
Lithium citrate Li3C3H4(OH)(COO)3 209.92     919-16-4
Lithium neodekanoate LiC9H19COO 178.24 27253-30-1
Lithium stearate LiC17H35COO 290.42   4485-12-5
Lithium 12-hydroxystearate LiC17H34(OH)COO 306.41   7620-77-1
Lithium is a soft, silver-white alkali metal. It oxidizes rapidly on contact with
air and develops a coating of gray oxide. Lithium can have an oxidation state of
either 0 or +1. On contact with water lithium breaks down the H2O molecules,
releasing hydrogen gas and leaving a strongly alkaline solution of lithium
hydroxide. Some other lithium compounds, notably the hydride, nitride, oxide,
amide and carbonate, are also alkaline either per se or due to their formation of
lithium hydroxide. For lithium compounds, solubility in water varies. The
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hydroxide dissolves readily in water, as do lithium chloride, lithium bromide
and some of the others (12, 16).
Occurrence, use
Lithium occurs naturally in low concentrations, but with considerable geographic
variation. Small amounts are in drinking water and various foods: total daily
intake of lithium has been estimated to be at most a few mg. Bottled mineral
water, however, may contain as much as 5.2 mg Li/liter (0.7 mmol Li/l), and
consumption of mineral supplements can add a further 5 – 6 mg (0.7 – 0.9 mmol)
Li/day. Lithium oxide is obtained from ore, and other lithium compounds and
metallic lithium are produced by further processing. Lithium salts are also
extracted from natural salt lakes (16). Lithium and lithium compounds are used
in batteries, as catalysts, and as reagents in organic syntheses. Metallic lithium is
also used in alloys and in the production of some lithium compounds. Lithium
carbonate is the most important compound in industrial use and is the material
from which many lithium salts are produced. The substance is also used in
aluminum production, as flux in production of glass, glazes and ceramics, and
in the construction industry. Another industrially important lithium compound
is lithium hydroxide. It is used mostly for production of lithium stearate, an
ingredient in e.g. lubricating oils. Lithium salts of fatty acids have uses ranging
from vehicle production to cosmetics. Lithium chloride and lithium bromide
are used in air conditioning systems to bind moisture. Lithium halides (lithium
chloride, lithium fluoride) are also used as fluxes in welding and soldering.
Some lithium compounds (the carbonate, citrate, sulfate and acetate) are used
medicinally. In Sweden in 2000, the primary consumers of lithium were the glass
and engineering industries, motor vehicle production and maintenance, and the
pulp and paper industry (16).
Uptake, distribution, excretion
Lithium is absorbed rapidly and completely by the digestive tract, although the
exact rate of absorption depends largely on the solubility of the lithium compound
in question. One study reports that, after a dilute solution of lithium chloride was
given orally to human subjects, maximum serum levels of lithium were reached
within 30 to 60 minutes and a plateau was reached after 12 to 24 hours (16). The
defined daily dose in Sweden for lithium treatment of affective disorders is 167
mg Li, although the necessary dose varies considerably from patient to patient.
The recommended serum level 12 hours after the most recent dose is generally
0.5 to 0.8 mmol Li/l, but in a few cases can be 0.9 to 1.2 mmol Li/l (16).
Human data also indicate that uptake of lithium via respiratory passages can be
fairly high, whereas uptake of lithium or lithium compounds via skin is regarded
as negligible. Uptake of lithium (dissolved in moisture) has been reported in
patients who had used respirators containing a lithium chloride coated heat and
moisture exchange unit for at least 5 days. Serum lithium rose from below the
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detection limit to 0.01 – 0.05 mmol/l or even as high as 0.1 mmol/l, and dropped
back below the detection limit within a few days after use of the respirator was
discontinued. A 7-year-old girl on a respirator was observed to have fluctuating
levels of lithium in serum, with a peak of 3.9 mmol/l on day 16. The authors
estimated that the amount of lithium chloride inhaled daily by adults using a
respirator with a new heat and moisture exchange unit (changed daily) amounted
to 80% of its lithium content, and was equivalent to a daily oral dose of 100 mg
lithium chloride or about 16 mg (2.3 mmol) Li. This is approximately a tenth of
the daily dose of lithium carbonate recommended for psychiatric patients. The
above data indicate, however, that clinically relevant and even toxic levels can
arise in children. Another work reports that more than 90% of the lithium chloride
in a new heat and moisture exchange unit had been deposited in a test lung after
20 minutes. However, a much lower inhalation uptake (17%) was measured in rats
with normal respiration rate that were exposed for 3 hours to lithium chloride in
aerosol form (from a solution containing 1% lithium) (16).
After uptake, lithium is distributed throughout the body, although little of it is
metabolized. The amount that binds to proteins in plasma or tissues is probably
quite small. At steady state (in human subjects), levels in liver, erythrocytes and
brain are lower than in serum, and levels in kidney, thyroid and bone are higher
than in serum. In humans, the distribution phase of lithium in serum and plasma
has a half time of about 2 to 6 hours. Excretion is primarily via the kidneys: over
95% of a single oral dose is excreted via the kidneys in unchanged form. One-
third to two-thirds of the dose is excreted in the first 6 to 12 hours and the rest
over the following 14 days. Lithium is freely filtered through the glomeruli, but
about 80% of it is resorbed along with sodium and water, mostly in the proximal
tubuli. With repeated administration, excretion of lithium rises during the first five
or six days until steady state is reached. For a single dose, the half time for the
elimination phase is 12 to 27 hours, but it can be as long as 58 hours for older
people or with long-term administration. Lithium passes the placental barrier, and
blood concentrations in maternal and umbilical blood are about the same. Lithium
is also secreted in breast milk. Levels in human breast milk are about 50% of
levels in serum (16).
Toxic effects
Human data
Intake of a single dose of lithium can cause acute poisoning. In such cases the
symptoms of poisoning are less severe and the poisoning is less dangerous than
other types of lithium poisoning, since the half time for elimination of lithium is
shorter in previously unexposed persons. The serum lithium level can be high —
over 4 mmol/l — without causing clinical symptoms of toxicity. Intake of a single
large dose of lithium, however, usually results in vomiting and diarrhea (16).
Poisoning can also appear in patients who have been taking lithium for some
time but whose serum levels have risen because of dose increases or deterioration
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in kidney function. Serum levels of 1.2 to 1.6 mmol Li/l are commonly associated
with a risk of poisoning, but toxic symptoms can also appear at recommended
therapeutic doses. The clinical picture of lithium intoxication is only weakly
correlated to the concentration of lithium in serum. Side effects are common
with therapeutic doses, i.e. with serum or plasma levels around 0.5 to 1.2 mmol
Li/l (measured 12 hours after administered dose). Some of the more common side
effects at a 12-hour serum lithium level of 0.5 to 0.8 mmol/l are moderate nephro-
genic diabetes insipidus, fine hand tremor, weight gain, elevated levels of thyroid-
stimulating hormones and hypothyroidism (16).
There are few studies of the effects of occupational exposure to lithium. In
a sketchily reported NIOSH study of personnel at a factory producing battery
systems, it is stated that workers in departments with higher lithium exposure
reported fewer health problems (poorly defined) than workers in a department
where lithium exposure was generally lower (17). Air concentrations (whole-shift,
personal monitors) were reported to be up to 0.12 mg Li/m3, and serum levels up
to 1.6 µmol Li/l. The authors concluded that, if earlier exposure levels were of the
same magnitude as those measured, it was very unlikely that lithium exposure at
the factory could cause toxic effects or side effects like those observed in
psychiatric patients.
Another NIOSH report (23) gives the frequency of several symptoms (from
questionnaires) in workers with various degrees of exposure to alkaline lithium
dust in a plant where lithium compounds were produced. In a comparison between
21 workers judged to be "exposed" and 23 workers judged to be "less exposed"
(57% and 39% smokers, respectively) it was found that complaints involving the
upper respiratory passages were more common among the "exposed" workers.
Sinus problems were reported by 43% (vs. 39%), runny noses by 38% (vs. 17%),
nosebleeds by 14% (vs. 0%), and dry throats by 52% (vs. 4%). Some other
symptoms, notably headaches (38% vs. 9%) and skin irritation (38% vs. 13%),
were also more common among the "exposed" workers. Symptoms of irritation,
especially sinus problems and runny noses, were reported to be most severe
among workers who bagged lithium hydroxide (pH 12.6) and lithium carbonate
(pH 11.2), and several workers complained of skin irritation and painful burns
from exposure to lithium hydroxide. Both personal and stationary monitors were
used to measure total dust and respirable dust, with specific analysis of lithium
content. The lithium levels in air (in total dust) registered by personal monitors at
these workplaces (bagging areas for lithium hydroxide and lithium carbonate)
were 0.02 – 0.05 and 0.54 – 1.84 mg Li/m3, respectively. In an area where lithium
carbonate was ground, the lithium level in air (in total dust) registered by personal
monitors was 1.08 – 3.53 mg Li/m3. Blood samples were taken from 18 "exposed"
and 6 "less exposed" workers, and lithium levels in blood were below the detec-
tion limit (0.1 mmol/l) in all but two of the samples. These two samples were
taken from two workers before a workshift, and contained 0.14 and 0.3 mmol Li/l.
There was no measurable increase in blood lithium content during the shift (23).
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Pronounced irritation of mucous membranes has also been reported with
exposure to 2 mg/m3 lithium/aluminum dust (lithium content up to 2.5% of the
alloy) (4). Further, lithium hydride, lithium tetrahydroaluminate and lithium
tetrahydroborate are reported to be both irritating and caustic (5, 7, 8, 18),
although there are little data on the air concentrations involved. However,
unpublished studies quoted in Patty’s (3) and the ACGIH document (1) report
symptoms of irritation in workers exposed to very low air concentrations of
lithium hydride (no information is given on exposure times or number of
workers). Patty's reports the data as follows: no effects observed in the concen-
tration interval 0 – 0.025 mg LiH/m3; tickling in the nose and sniffles at 0.025 –
0.10 mg LiH/m3 (but these air concentrations were tolerable for workers
accustomed to the exposure); and pronounced nasal irritation and some coughing
at concentrations between 0.10 and 0.50 mg LiH/m3 (this level was not tolerable).
At levels between 0.50 and 1.0 mg LiH/m3 nasal irritation and coughing were
pronounced, and some subjects had irritated eyes. At air concentrations between
1 and 5 mg LiH/m3 all these effects were severe and skin irritation was also seen.
Skin irritation also occurred at lower air concentrations during hot weather or in
connection with perspiration. The ACGIH document presents the information as
follows: the maximum air concentration tolerable for short periods is 0.5 mg
LiH/m3. At 0.05 mg LiH/m3 workers rapidly become acclimated, but this concen-
tration is unpleasant for individuals who are not accustomed to it. Persons more
accustomed to exposure complained of nose and eye irritation at levels above
0.1 mg LiH/m3 and itching of exposed skin at levels exceeding approximately
0.2 mg LiH/m3.
Animal data
Single oral doses of various lithium compounds have moderate acute toxicity. The
LD50 for oral administration of lithium chloride was reported to be 757 mg/kg b.w.
for rats and 850 mg/kg b.w. for rabbits, equivalent respectively to 124 and 139 mg
(18 and 20 mmol) Li/kg b.w. For oral administration of lithium carbonate, the
reported LD50 is 500 mg/kg b.w. for dogs and 710 mg/kg b.w. for mice, or respec-
tively 94 and 133 mg (14 and 19 mmol) Li/kg b.w. (16).
In one study with rats, the LC50 (death within 14 days) was calculated to
be 1800 mg/m3 for 4 hours of exposure to an aerosol containing 80% lithium
carbonate and 20% lithium hydroxide and lithium oxide (aerosol 1) (11). The
corresponding LC50 (rats, 4 hours, 14 days) was 960 mg/m3 for an aerosol
containing primarily lithium hydroxide with about 23% lithium carbonate (aerosol
2), and 940 mg/m3 for a mixture of lithium oxide with a small amount of lithium
hydroxide and about 12% lithium carbonate (aerosol 3) (22). Four air concen-
trations of each aerosol were used in the exposures: 620, 1400, 2300 and 2600
mg/m3 for aerosol 1; 570, 840, 1200 and 1500 mg/m3 for aerosol 2; and 500, 750,
1000 and 1500 mg/m3 for aerosol 3. The animals were observed daily, and those
that died, as well as those that were killed (14 or 28 days after the exposure), were
given histopathological examinations. Dose-dependent effects such as coughing,
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breathing difficulty, weight loss, and dried blood and mucus around eyes, nose
and mouth, were noted. The most prominent substance-related histopathological
changes were the indications of severe irritation in the upper respiratory passages
(ulcerative/necrotic laryngitis, erosive/ulcerative rhinitis, squamous metaplasia)
and in some cases secondary lung damage. Effects on thymus (atrophy, drastic
reduction of lymphocytes) were also observed, but were considered to be a non-
specific reaction to systemic stress. For all three aerosols, the irritation effects
were observed primarily in the two highest dose groups. The effects of aerosol 1
(containing primarily lithium carbonate) were generally milder and less wide-
spread than the effects of the other two mixtures. For example, no rhinitis,
laryngitis or alveolitis was seen in any of the 16 animals exposed to 620 mg/m3
of aerosol 1, whereas these effects were seen in a few animals in the two lowest
dose groups exposed to the other two aerosols (11, 22).
When laboratory animals were exposed to 5 – 55 mg LiH/m3 (4 – 48 mg Li/m3)
for 4 to 7 hours (50% relative humidity), coughing and sneezing were reported at
all concentrations. At levels above 10 mg LiH/m3 corrosion was observed on areas
of the fur and skin. Some rats also had severely inflamed and irritated eyes, and in
a few rats the nasal septum was destroyed (26). These effects were attributed to
the alkalinity of the hydrolysis product lithium hydroxide. In the same study, sores
were observed on noses and forepaws, inflammation in eyes, partial sloughing of
mucous epithelium in trachea, and in some lungs emphysema (probably secondary
damage) after exposure to about 5 mg LiH/m3, 4 hours/day for 5 days, both when
the animals were killed immediately after the exposure and up to 14 days later
(Table 2). No exposure-related histopathological changes were seen in lungs,
liver, kidneys, trachea or lymph nodes 2 to 5 months after exposure was ended
(26). No significant inflammatory changes were observed in the lungs of rabbits
exposed to a lithium chloride aerosol containing 0.6 or 1.9 mg Li/m3, 6 hours/day,
5 days/week for 4 to 8 weeks (optical and electron microscope, bronchial lavage)
(14).
Salt balance has a major influence on the toxicity of lithium. In experiments
with dogs, it was observed that animals that received daily oral doses of lithium
chloride (8.2 mg Li/kg b.w.; 1.2 mmol Li/kg b.w.) and had normal sodium intake
survived the entire experiment period of 150 days, whereas the same dose was
lethal within 12 to 18 days for animals with low sodium intake (21). When rats
were given a diet low in sodium and daily intraperitoneal injections of lithium
chloride (3.5 – 69 mg Li/kg b.w./day; 0.5 – 10 mmol Li /kg b.w./day), a daily dose
of 6.9 mg (1 mmol) Li/kg b.w. resulted in a temporary increase of serum lithium
levels, whereas 21 mg (5 mmol) Li/kg b.w./day yielded a steady increase after a
few days. Rats given extra sodium had steadily increasing lithium levels in serum
at a dose of 35, but not 21, mg Li/kg b.w./day. Animals with lithium accumulation
had deteriorating renal function, leading to death. Histological examination
revealed acute degenerative changes in proximal tubuli, but no changes in other
examined organs except moderate vacuolization of the adrenal cortex. Lithium-
induced polyurea (the initial indication of renal toxicity) was reversible if the
61
lithium injections were stopped (24). The author concluded from this study that
lithium affects primarily renal function.
Mutagenicity, carcinogenicity
Lithium compounds (the chloride, citrate, carbonate, acetate, sulfate and
hypochlorite) have been tested for mutagenicity, DNA damage, chromosome
aberrations and sister chromatid exchanges in a number of in vitro and in vivo
studies (16). Many of these studies yielded negative results, but positive results
were also reported — although usually at high doses (equivalent to therapeutic
doses or higher). A possible explanation for the observation of genotoxic effects
at higher doses may be increased cell survival, since lithium inhibits apoptosis
by inhibiting the enzyme glycogen synthase kinase-3 (16). At low dose levels
genotoxic effects (chromosome aberrations) have been reported in only a few,
poorly written studies and in a single study of lithium hypochlorite. In this latter
study chromosome aberrations were observed in CHO cells in vitro, although
lithium hypochlorite was negative in other mutagenicity/genotoxicity tests (16).
It should be noted that the hypochlorites of calcium and sodium have also been
reported to increase chromosome aberrations in mammalian cells, which suggests
that the effect can probably be attributed to the hypochlorite ion. The great
majority of studies of chromosome damage in leukocytes, lymphocytes and bone
marrow cells of patients treated with lithium indicate that lithium therapy does
not increase risk of chromosome aberrations or sister chromatid exchanges (16).
Weiner (27) concludes that present knowledge, based on all data from human
studies, animal studies and genotoxicity studies, indicates that the lithium ion is
neither mutagenic nor damaging to DNA, and causes no chromosome aberrations
in patients.
There are no available data indicating that lithium has oncogenic effects (18,
20, 27).
Effects on reproduction
Human data
An elevated incidence of a rare heart defect (Epstein's anomaly) in children born
to mothers on lithium treatment during their first trimester was reported in the
1970s. The data originated in the Lithium Baby Register, a register containing
retrospective, voluntarily submitted data (2, 13). Later studies have indicated that
lithium therapy is associated with little or no risk to fetuses (16). In 1994 Cohen et
al. (6) assessed all the controlled epidemiological studies that had been published
after the alarming reports from the Lithium Baby Register and concluded that the
risk of teratogenic effects from administration of lithium during the first trimester
is lower than initially believed. The question of whether prenatal lithium exposure
affects postnatal development has been examined in a few studies. In a follow-up
study of 60 children without congenital malformations from the Lithium Baby
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Register, no elevation in incidence of physical or mental abnormality was
observed when these babies were compared with unexposed siblings (25). In
a study in which “milestones in development” (e.g. sitting, crawling, talking,
walking) of 22 children of mother treated with lithium were compared with
controls, no difference was noted (13). As for possible effects on reproduction
in men undergoing lithium treatment, existing data are too scanty to allow a
conclusion (16).
Animal data
In animal experiments, teratogenic effects due to administration of lithium have
been reported to be dose-related. In one review (15), the NOAEL for effects on
fetuses and mothers was given as 10 mg (1.4 mmol) Li/kg b.w./day when lithium
was administered during the critical periods for cell differentiation and organo-
genesis. Defects in the heart/circulatory system have not been observed in animal
experiments (16).
Significant inhibition of spermatogenesis has been reported with daily sub-
cutaneous injections of 0.3 mg (0.04 mmol) Li/kg b.w. as lithium chloride for
15 days (10). It was found in this study that lithium affected testicular function
by reducing the serum levels of FSH, LH, prolactin and testosterone. Reduced
activity of key enzymes in androgen biosyntheses was also observed. Admini-
stration of lithium chloride for 20 and 25 days also reduced the weights of testes,
prostata and seminal vesicles. Lithium level in serum was reported to be about 0.5
mmol/l (10). The same authors showed that a prolactin injection 8 hours after the
treatment with lithium chloride protected against most of these effects (9).
Effects on fertility at doses which seem to have no other effects on the animals
were described in an incompletely reported study in which mice of both sexes
were given drinking water containing lithium chloride (10 – 200 mmol Li/l; 69 –
1388 mg Li/l). Fewer litters and elevated mortality among the pups during the
period between birth and weaning were reported in the group that received 50
mmol (347 mg) Li/l from 2 weeks before mating until the pups were weaned.
The plasma level was reported to be about 0.7 mmol Li/l. When the animals
received 50 mmol Li/l starting five weeks before mating, postnatal growth and
development were also retarded. No reproduction was reported in animals given
100 mmol (694 mg) Li/l (19).
Dose-effect / dose-response relationships
There are little data that can be used to estimate a dose-effect or dose-response
relationship for occupational exposure to lithium. Several studies have reported
irritation of respiratory passages, eyes and skin, and sometimes skin burns, with
exposure to metallic lithium and alkaline lithium compounds. In one study
(reviewed in Reference 3) slight nasal irritation is reported at exposure to 0.025 –
0.10 mg LiH/m3, and pronounced nasal irritation and coughing at 0.10 – 0.50 mg
LiH/m3. Exposure levels of 0.50 – 1.0 mg LiH/m3 resulted in severe nasal
irritation and coughing, and some workers had irritated eyes (Table 1). Lithium
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hydroxide seems to be irritating at approximately the same air concentrations. One
study of lithium hydroxide exposure (23) reports symptoms of irritation of upper
respiratory passages and skin with exposure to about 0.02 – 0.05 mg Li/m3. For
exposure to lithium carbonate, irritation of the upper respiratory passages is
reported at levels around 0.5 to 1.8 mg Li/m3 (23). No effects other than irritation
and erosion have been attributed to occupational exposure to lithium or lithium
compounds. Available data also indicate that serum levels of lithium in exposed
workers are very low compared to levels in psychiatric patients medicated with
lithium. A theoretical calculation of daily uptake at an air concentration of 1 mg
Li/m3 yields a value of 10 mg Li (assuming that 10 m3 air are inhaled in 8 hours
and uptake is 100%). This should be compared with the defined daily dose in
Sweden — 167 mg Li — when lithium is used to treat psychiatric patients.
Dose-effect relationships observed in laboratory animals exposed by inhalation
to lithium hydride are summarized in Table 2.
Table 1. Dose-effect data for occupational exposure to lithium.
Exposure level (mg/m3) Effect   Ref.
as Li compound as Li
0-0.025 (LiH) 0-0.022 No effect 3
0.069-0.17* (LiOH) 0.02-0.05* Symptoms of irritation 23
0.025-0.10 (LiH) 0.022-0.09 Tickling in nose, sniffles
Tolerable for workers accustomed to it
3
0.05 (LiH) 0.04 Workers acclimate rapidly, unpleasant for people
not used to it
1
0.10-0.50 (LiH) 0.09-0.44 Clear nasal irritation, some coughing
Not tolerable
3
>0.1 (LiH) >0.09 Eye and nose irritation in persons somewhat
accustomed to exposure
1
>0.2 (LiH) >0.17 Itching of exposed skin 1
0.5 (LiH) 0.44 Maximum air concentration tolerable for brief
periods
1
0.50-1.0 (LiH) 0.44-0.87 Severe nasal irritation, coughing
Some workers had irritated eyes
3
2.88-9.8* (Li2CO3) 0.54-1.84* Symptoms of respiratory irritation 23
1.0-5.0 (LiH) 0.87-4.4 Severe respiratory irritation
Skin irritation
3
*Amount in total dust as registered by personal monitors.
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Table 2. Exposure-effect relationships observed in laboratory animals exposed by
inhalation to lithium hydride (from Reference 26).
Exposure (LiH) Species
(number of animals)
Effect
5 mg/m3, 4 hours/day,
5 days
Rat (10), Guinea pig (3),
Mouse (10), Rabbit (3)
Some sores on noses and forepaws,
emphysema in a few lungs
Guinea pig: eye inflammation
Rabbit: eye inflammation
Mouse: partial sloughing of mucous
epithelium in trachea
45 mg/m3, 4 hours Rabbit (2) Damage to nose and forepaws, acute eye
inflammation
49 mg/m3, 4 hours Guinea pig (2) No external damage
55 mg/m3, 4 hours Rat (8) Erosions on noses and forepaws
Mouse (8) Erosions on noses and forepaws,
Partial sloughing of mucous epithelium in
trachea
Conclusions
The critical effect of occupational exposure to lithium and lithium compounds
is irritation of the respiratory passages. Exposure to lithium and alkaline lithium
compounds can result in irritation of respiratory passages, eyes and skin, and
occasionally skin erosion. Irritation of upper respiratory passages has been
reported in workers exposed to 0.02 – 0.09 mg Li/m3 as lithium hydride. Symp-
toms of irritation have been reported at exposure to about the same air levels of
lithium hydroxide.
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Summary
Montelius J (ed). Scientific Basis for Swedish Occupational Standards. XXIV.
Arbete och Hälsa 2003:16, pp 1-73. National Institute for Working Life, Stockholm.
Critical review and evaluation of those scientific data which are relevant as a background
for discussion of Swedish occupational exposure limits. This volume consists of the
consensus reports given by the Criteria Group at the Swedish National Institute for
Working Life from July, 2002 through June, 2003.
Key Words: Cadmium, Chlorobenzene, Diesel exhaust, Lithium, Litium compounds,
Occupational exposure limit (OEL), Risk assessment, Scientific basis,
Toxicology, Triethanolamine.
Sammanfattning
Montelius J (ed). Vetenskapligt underlag för hygieniska gränsvärden. XXIV. Arbete och
Hälsa 2003:16, s 1-73. Arbetslivsinstitutet, Stockholm.
Sammanställningar baserade på kritisk genomgång och värdering av de vetenskapliga
fakta, vilka är relevanta som underlag för fastställande av hygieniskt gränsvärde.
Volymen omfattar de underlag som avgivits från Kriteriegruppen för hygieniska
gränsvärden under perioden juli 2002 - juni 2003.
Nyckelord: Dieselavgaser, Hygieniskt gränsvärde, Kadmium, Klorbensen, Litium,
Litiumföreningar, Riskvärdering, Toxikologi, Trietanolamin, Vetenskapligt
underlag.
En svensk version av dessa vetenskapliga underlag finns publicerad i Arbete och Hälsa
2003:15.
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APPENDIX
Consensus reports in this and previous volumes
Substance Consensus date Volume in Arbete
och Hälsa (No.)
Acetaldehyde February 17, 1987 1987:39 (VIII)
Acetamide December 11, 1991 1992:47 (XIII)
Acetic acid June15, 1988 1988:32 (IX)
Acetone October 20, 1987 1988:32 (IX)
Acetonitrile September 12, 1989 1991:8 (XI)
Acrylamide April 17, 1991 1992:6 (XII)
Acrylates December 9, 1984 1985:32 (VI)
Acrylonitrile April 28, 1987 1987:39 (VIII)
Aliphatic amines August 25, 1982 1983:36 (IV)
Aliphatic hydrocarbons, C10-C15 June 1, 1983 1983:36 (IV)
Aliphatic monoketons September 5, 1990 1992:6 (XII)
Allyl alcohol September 9, 1986 1987:39 (VIII)
Allylamine August 25, 1982 1983:36 (IV)
Allyl chloride June 6, 1989 1989:32 (X)
Aluminum April 21, 1982 1982:24 (III)
revised September 14, 1994 1995:19 (XVI)
p-Aminoazobenzene February 29, 1980 1981:21 (I)
Ammonia April 28, 1987 1987:39 (VIII)
Amylacetate March 23, 1983 1983:36 (IV)
revised June 14, 2000 2000:22 (XXI)
Aniline October 26, 1988 1989:32 (X)
Anthraquinone November 26,1987 1988:32 (IX)
Antimony + compounds December 8, 1999 2000:22 (XXI)
Arsenic, inorganic December 9, 1980 1982:9 (II)
revised February 15, 1984 1984:44 (V)
Arsine October 20, 1987 1988:32 (IX)
Asbestos October 21, 1981 1982:24 (III)
Barium June 16, 1987 1987:39 (VIII)
revised January 26, 1994 1994:30 (XV)
Benzene March 4, 1981 1982:9 (II)
revised February 24, 1988 1988:32 (IX)
Benzoyl peroxide February 13, 1985 1985:32 (VI)
Beryllium April 25, 1984 1984:44 (V)
Borax October 6, 1982 1983:36 (IV)
Boric acid October 6, 1982 1983:36 (IV)
Boron Nitride January 27 1993 1993:37 (XIV)
Butadiene October 23, 1985 1986:35 (VII)
1-Butanol June 17, 1981 1982:24 (III)
Butanols June 6, 1984 1984:44 (V)
Butyl acetate June 6, 1984 1984:44 (V)
Butyl acetates February 11, 1998 1998:25 (XIX)
Butylamine August 25, 1982 1983:36 (IV)
Butyl glycol October 6, 1982 1983:36 (IV)
Cadmium January 18, 1980 1981:21 (I)
revised February 15, 1984 1984:44 (V)
revised May 13, 1992 1992:47 (XIII)
revised February 5 2003 2003:16 (XXIV)
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Calcium hydroxide February 24, 1999 1999:26 (XX)
Calcium nitride January 27, 1993 1993:37 (XIV)
Calcium oxide February 24, 1999 1999:26 (XX)
Caprolactam October 31, 1989 1991:8 (XI)
Carbon monoxide December 9, 1981 1982:24 (III)
Cathecol September 4, 1991 1992:47 (XIII)
Chlorine December 9, 1980 1982:9 (II)
Chlorine dioxide December 9, 1980 1982:9 (II)
Chlorobenzene September 16 1992 1993:37 (XIV)
revised April 2 2003 2003:16 (XXIV)
o-Chlorobenzylidene malononitrile June 1, 1994 1994:30 (XV)
Chlorocresol December 12, 1990 1992:6 (XII)
Chlorodifluoromethane June 2, 1982 1982: 24 (III)
Chlorophenols September 4, 1985 1986:35 (VII)
Chloroprene April 16, 1986 1986:35 (VII)
Chromium December 14, 1979 1981:21 (I)
revised May 26, 1993 1993:37 (XIV)
revised May 24, 2000 2000:22 (XXI)
Chromium trioxide May 24, 2000 2000:22 (XXI)
Coal dust September 9, 1986 1987:39 (VIII)
Cobalt October 27, 1982 1983:36 (IV)
Copper October 21, 1981 1982:24 (III)
Cotton dust February14, 1986 1986:35 (VII)
Creosote October 26, 1988 1989:32 (X)
Cresols February 11, 1998 1998:25 (XIX)
Cumene June 2, 1982 1982:24 (III)
Cyanamid September 30, 1998 1999:26 (XX)
Cyanoacrylates March 5, 1997 1997:25 (XVIII)
Cycloalkanes, C5-C15 April 25, 1984 1984:44 (V)
Cyclohexanone March 10, 1982 1982:24 (III)
revised February 24 1999 1999:26 (XX)
Cyclohexanone peroxide February 13, 1985 1985:32 (VI)
Cyclohexylamine February 7, 1990 1991:8 (XI)
Desflurane May 27, 1998 1998:25 (XIX)
Diacetone alcohol December 14, 1988 1989:32 (X)
Dichlorobenzenes February 11, 1998 1998:25 (XIX)
1,2-Dibromo-3-chloropropane May 30, 1979 1981:21 (I)
Dichlorodifluoromethane June 2, 1982 1982:24 (III)
1,2-Dichloroethane February 29, 1980 1981:21 (I)
Dichloromethane February 29, 1980 1981:21 (I)
Dicumyl peroxide February 13, 1985 1985:32 (VI)
Dicyclopentadiene March 23, 1994 1994:30 (XV)
Diesel exhaust December 4 2002 2003:16 (XXIV)
Diethanolamine September 4, 1991 1992:47 (XIII)
Diethylamine August 25, 1982 1983:36 (IV)
2-Diethylaminoethanol January 25, 1995 1995:19 (XVI)
Diethylene glycol September 16, 1992 1993:37 (XIV)
Diethyleneglycol ethylether + acetate December 11, 1996 1997:25 (XVIII)
Diethyleneglycol methylether + acetate March 13, 1996 1996:25 (XVII)
Diethyleneglycol monobutylether January 25, 1995 1995:19 (XVI)
Diethylenetriamine August 25, 1982 1983:36 (IV)
revised January 25, 1995 1995:19 (XVI)
Diisocyanates April 8, 1981 1982:9 (II)
revised April 27, 1988 1988:32 (IX)
Diisopropylamine February 7, 1990 1991:8 (XI)
N,N-Dimethylacetamide March 23, 1994 1994:30 (XV)
Dimethyl adipate December 9, 1998 1999:26 (XX)
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Dimethylamine December 10, 1997 1998:25 (XIX)
N,N-Dimethylaniline December 12, 1989 1991:8 (XI)
Dimethyldisulfide September 9, 1986 1987:39 (VIII)
Dimethylether September 14, 1994 1995:19 (XVI)
Dimethylethylamine June 12, 1991 1992:6 (XII)
Dimethylformamide March 23, 1983 1983:36 (IV)
Dimethyl glutarate December 9, 1998 1999:26 (XX)
Dimethylhydrazine January 27, 1993 1993:37 (XIV)
Dimethyl succinate December 9, 1998 1999:26 (XX)
Dimethylsulfide September 9, 1986 1987:39 (VIII)
Dimethylsulfoxide, DMSO December 11, 1991 1992:47 (XIII)
Dioxane August 25, 1982 1983:36 (IV)
revised March 4, 1992 1992:47 (XIII)
Diphenylamine January 25, 1995 1995:19 (XVI)
4,4'-Diphenylmethanediisocyanate (MDI) April 8, 1981 1982:9 (II)
reviderat May 30 2001 2001:20 (XXII)
Dipropylene glycol May 26, 1993 1993:37 (XIV)
Dipropyleneglycol monomethylether December 12, 1990 1992:6 (XII)
Disulfiram October 31, 1989 1991:8 (XI)
Enzymes, industrial June 5, 1996 1996:25 (XVII)
Ethanol May 30, 1990 1991:8 (XI)
Ethanolamine September 4, 1991 1992:47 (XIII)
Ethylacetate March 28, 1990 1991:8 (XI)
Ethylamine August 25, 1982 1983:36 (IV)
Ethylamylketone September 5, 1990 1992:6 (XII)
Ethylbenzene December 16, 1986 1987:39 (VIII)
Ethylchloride December 11, 1991 1992:47 (XIII)
Ethylene December 11, 1996 1997:25 (XVIII)
Ethylene chloride February 29, 1980 1981:21 (I)
Ethylene diamine August 25, 1982 1983:36 (IV)
Ethylene glycol October 21, 1981 1982:24 (III)
Ethylene glycol methylether + acetate June 2, 1999 1999:26 (XX)
Ethyleneglycol monoisopropylether November 16, 1994 1995:19 (XVI)
Ethyleneglycol monopropylether + acetate September 15, 1993 1994:30 (XV)
Ethylene oxide December 9, 1981 1982:24 (III)
Ethylenethiourea September 27, 2000 2001:20 (XXII)
Ethylether January 27, 1993 1993:37 (XIV)
Ethylglycol October 6, 1982 1983:36 (IV)
Ferbam September 12, 1989 1991:8 (XI)
Ferric dimethyldithiocarbamate September 12, 1989 1991:8 (XI)
Flour dust December 10, 1997 1998:25 (XIX)
Formaldehyde June 30, 1979 1981:21 (I)
revised August 25, 1982 1983:36 (IV)
Formamide December 12, 1989 1991:8 (XI)
Formic acid June 15, 1988 1988:32 (IX)
Furfural April 25, 1984 1984:44 (V)
Furfuryl alcohol February 13, 1985 1985:32 (VI)
Gallium + Gallium compounds January 25, 1995 1995:19 (XVI)
Glutaraldehyde September 30 1998 1999:26 (XX)
Glycol ethers October 6, 1982 1983:36 (IV)
Glyoxal September 13, 1996 1996:25 (XVII)
Grain dust December 14, 1988 1989:32 (X)
Graphite December 10, 1997 1998:25 (XIX)
Halothane April 25, 1985 1985:32 (VI)
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2-Heptanone September 5, 1990 1992:6 (XII)
3-Heptanone September 5, 1990 1992:6 (XII)
Hexachloroethane September 15, 1993 1994:30 (XV)
Hexamethylenediisocyanate (HDI) April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
Hexamethylenetetramine August 25, 1982 1983:36 (IV)
n-Hexane January 27, 1982 1982:24 (III)
2-Hexanone September 5, 1990 1992:6 (XII)
Hexyleneglycol November 17, 1993 1994:30 (XV)
Hydrazine May 13, 1992 1992:47 (XIII)
Hydrogen bromide February 11, 1998 1998:25 (XIX)
Hydrogen cyanide February 7 2001 2001:20 (XXII)
Hydrogen fluoride April 25, 1984 1984:44 (V)
Hydrogen peroxide April 4, 1989 1989:32 (X)
Hydrogen sulfide May 4, 1983 1983:36 (IV)
Hydroquinone October 21, 1989 1991:8 (XI)
Indium March 23, 1994 1994:30 (XV)
Industrial enzymes June 5, 1996 1996:25 (XVII)
Isocyanic Acid (ICA) December 5 2001 2002:19 (XXIII)
Isophorone February 20, 1991 1992:6 (XII)
Isopropanol December 9, 1981 1982:24 (III)
Isopropylamine February 7, 1990 1991:8 (XI)
Isopropylbenzene June 2, 1982 1982:24 (III)
Lactates March 29, 1995 1995:19 (XVI)
Lactate esters June 2, 1999 1999:26 (XX)
Lead, inorganic February 29, 1980 1981:21 (I)
revised September 5, 1990 1992:6 (XII)
Lithium and lithium compounds June 4 2003 2003:16 (XXIV)
Lithium boron nitride January 27, 1993 1993:37 (XIV)
Lithium nitride January 27, 1993 1993:37 (XIV)
Maleic anhydride September 12, 1989 1991:8 (XI)
Manganese February 15, 1983 1983:36 (IV)
revised April 17, 1991 1992:6 (XII)
revised June 4, 1997 1997:25 (XVIII)
Man made mineral fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Mercury, inorganic April 25, 1984 1984:44 (V)
Mesityl oxide May 4, 1983 1983:36 (IV)
Metal stearates, some September 15, 1993 1994:30 (XV)
Methacrylates September 12, 1984 1985:32 (VI)
Methanol April 25, 1985 1985:32 (VI)
Methyl acetate March 28 1990 1991:8 (XI)
Methylamine August 25, 1982 1983:36 (IV)
Methylamyl alcohol March 17, 1993 1993:37 (XIV)
Methyl bromide April 27, 1988 1988:32 (IX)
Methyl chloride March 4, 1992 1992:47 (XIII)
Methyl chloroform March 4, 1981 1982:9 (II)
Methylene chloride February 29, 1980 1981:21 (I)
4,4'-Methylene dianiline June 16, 1987 1987:39 (VIII)
revised October 3 2001 2002:19 (XXIII)
Methyl ethyl ketone February 13, 1985 1985:32 (VI)
Methyl ethyl ketone peroxide February 13, 1985 1985:32 (VI)
Methyl formate December 12, 1989 1991:8 (XI)
Methyl glycol October 6, 1982 1983:36 (IV)
Methyl iodide June 30, 1979 1981:21 (I)
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Methylisoamylamine September 5, 1990 1992:6 (XII)
Methylisoamylketone February 6 2002 2002:19 (XXIII)
Methylisocyanate (MIC) December 5 2001 2002:19 (XXIII)
Methyl mercaptane September 9, 1986 1987:39 (VIII)
Methyl methacrylate March 17, 1993 1993:37 (XIV)
Methyl pyrrolidone June 16, 1987 1987:39 (VIII)
α-Methylstyrene November 1 2000 2001:20 (XXII)
Methyl-t-butyl ether November 26, 1987 1988:32 (IX)
revised September 30, 1998 1999:26 (XX)
Mixed solvents, neurotoxicity April 25, 1985 1985:32 (VI)
Molybdenum October 27, 1982 1983:36 (IV)
Monochloroacetic acid February 20, 1991 1992:6 (XII)
Monochlorobenzene September 16,1993 1993:37 (XIV)
Monomethylhydrazine March 4, 1992 1992:47 (XIII)
Mononitrotoluene February 20, 1991 1992:6 (XII)
Monoterpenes February 17, 1987 1987:39 (VIII)
Morpholine December 8, 1982 1983:36 (IV)
revised June 5, 1996 1996:25 (XVII)
Naphthalene May 27, 1998 1998:25 (XIX)
Natural crystallinic fibers (except asbestos) June 12, 1991 1992:6 (XII)
Nickel April 21, 1982 1982:24 (III)
Nitroethane April 4, 1989 1989:32 (X)
Nitrogen oxides December 11, 1985 1986:35 (VII)
Nitroglycerin February 13, 1985 1985:32 (VI)
Nitroglycol February 13, 1985 1985:32 (VI)
Nitromethane January 6, 1989 1989:32 (X)
Nitropropane October 28, 1986 1987:39 (VIII)
2-Nitropropane March 29, 1995 1995:19 (XVI)
Nitroso compounds December 12, 1990 1992:6 (XII)
Nitrosomorpholine December 8, 1982 1983:36 (IV)
Nitrotoluene February 20, 1991 1992:6 (XII)
Nitrous oxide December 9, 1981 1982:24 (III)
Oil mist April 8, 1981 1982:9 (II)
Organic acid anhydrides, some September 12, 1989 1991:8 (XI)
Oxalic acid February 24, 1988 1988:32 (IX)
Ozone April 28, 1987 1987:39 (VIII)
Paper dust February 7, 1990 1991:8 (XI)
Pentaerythritol November 16, 1994 1995:19 (XVI)
1,1,1,2,2-Pentafluoroethane February 24, 1999 1999:26 (XX)
Pentyl acetate June 14, 2000 2000:22 (XXI)
Peroxides, organic February 13, 1985 1985:32 (VI)
Phenol February 13, 1985 1985:32 (VI)
Phosphorous chlorides September 30, 1998 1999:26 (XX)
Phosphorous oxides February 11, 1998 1998:25 (XIX)
Phthalates December 8, 1982 1983:36 (IV)
Phthalic anhydride September 12, 1989 1991:8 (XI)
Piperazine September 12, 1984 1985:32 (VI)
Plastic dusts December 16, 1986 1987:39 (VIII)
Platinum June 4, 1997 1997:25 (XVIII)
Polyaromatic hydrocarbons February 15, 1984 1984:44 (V)
Polyisocyanates April 27, 1988 1988:32 (IX)
Potassium aluminium fluoride June 4, 1997 1997:25 (XVIII)
Potassium cyanide February 7 2001 2001:20 (XXII)
Potassium dichromate May 24, 2000 2000:22 (XXI)
Potassium hydroxide Marsh 15, 2000 2000:22 (XXI)
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2-Propanol December 9, 1981 1982:24 (III)
Propene September 13, 1996 1996:25 (XVII)
Propionic acid November 26, 1987 1988:32 (IX)
Propylacetate September 14, 1994 1995:19 (XVI)
Propylene glycol June 6, 1984 1984:44 (V)
Propylene glycol-1,2-dinitrate May 4, 1983 1983:36 (IV)
Propylene glycol monomethylether October 28, 1986 1987:39 (VIII)
Propylene oxide June 11, 1986 1986:35 (VII)
Pyridine May 13, 1992 1992:47 (XIII)
Quartz March 13, 1996 1996:25 (XVII)
Resorcinol September 4, 1991 1992:47 (XIII)
Selenium December 11, 1985 1986:35 (VII)
revised February 22, 1993 1993:37 (XIV)
Sevoflurane May 27, 1998 1998:25 (XIX)
Silica March 13, 1996 1996:25 (XVII)
Silver October 28, 1986 1987:39 (VIII)
Sodium cyanide February 7 2001 2001:20 (XXII)
Sodium hydroxide August 24, 2000 2000:22 (XXI)
Stearates, metallic, some September 15, 1993 1994:30 (XV)
Stearates, non-metallic, some November 17, 1993 1994:30 (XV)
Strontium January 26, 1994 1994:30 (XV)
Styrene February 29, 1980 1981:21 (I)
revised October 31, 1989 1991:8 (XI)
Sulfur dioxide April 25, 1985 1985:32 (VI)
Sulfur fluorides March 28, 1990 1991:8 (XI)
Synthetic inorganic fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Synthetic organic and inorganic fibers May 30, 1990 1991:8 (XI)
Talc dust June 12, 1991 1992:6 (XII)
Terpenes, mono- February 17, 1987 1987:39 (VIII)
Tetrabromoethane May 30, 1990 1991:8 (XI)
Tetrachloroethane June 4, 1997 1997:25 (XVIII)
Tetrachloroethylene February 29, 1980 1981:21 (I)
1,1,1,2-Tetrafluoroethane March 29, 1995 1995:19 (XVI)
Tetrahydrofuran October 31, 1989 1991:8 (XI)
Tetranitromethane April 4, 1989 1989:32 (X)
Thioglycolic acid June 1, 1994 1994:30 (XV)
Thiourea December 1, 1987 1988:32 (IX)
revised June 2, 1999 1999:26 (XX)
Thiram October 31, 1989 1991:8 (XI)
Thiurams, some October 31, 1989 1991:8 (XI)
Titanium dioxide February 21, 1989 1989:32 (X)
Toluene February 29, 1980 1981:21 (I)
revised February 6 2002 2002:19 (XXIII)
Toluene-2,4-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,6-diamine November 1, 2000 2001:20 (XXII)
Toluene-2,4-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
Toluene-2,6-diisocyanate April 8, 1981 1982:9 (II)
revised May 30, 2001 2001:20 (XXII)
1,1,1-Trifluoroethane February 24, 1999 1999:26 (XX)
Trichlorobenzene September 16, 1993 1993:37 (XIV)
1,1,1-Trichloroethane March 4, 1981 1982:9 (II)
Trichloroethylene December 14, 1979 1981:21 (I)
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Trichlorofluoromethane June 2, 1982 1982:24 (III)
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982:24 (III)
Triethanolamine August 25, 1982 1983:36 (IV)
revised October 23 2002 2003:16 (XXIV)
Triethylamine December 5, 1984 1985:32 (VI)
Trimellitic anhydride September 12, 1989 1991:8 (XI)
Trimethylolpropane November 16, 1994 1995:19 (XVI)
Trinitrotoluene April 17, 1991 1992:6 (XII)
Vanadium March 15, 1983 1983:36 (IV)
Vinyl acetate June 6, 1989 1989:32 (X)
Vinyl toluene December 12, 1990 1992:6 (XII)
White spirit December 16, 1986 1987:39 (VIII)
Wood dust June 17, 1981 1982:9 (II)
revised June 25, 2000 2000:22 (XXI)
Xylene February 29, 1980 1981:21 (I)
Zinc April 21, 1982 1982:24 (III)
Zinc chromate May 24, 2000 2000:22 (XXI)
Zinc dimethyl dithiocarbamate September 12, 1989 1991:8 (XI)
Ziram September 12, 1989 1991:8 (XI)
Sent for publication December 2003
